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Part I. Studies on the potent hepatitis C virus 
NS5A inhibitors* 
 
Hepatitis C virus (HCV) belongs to the hepacivirus genus in the Flaviviridae 
family as a single stranded RNA virus (50 nm in size) and its infection often 
leads to serious disorders such as liver cirrhosis, followed eventually by 
hepatocellular carcinoma. HCV RNA consists of structural and nonstructural 
proteins. Especially, several non-structural proteins (NS2, NS3, NS4A, NS4B, 
NS5A and NS5B) involved in the reproduction of HCV are of great importance 
for the identification of new therapeutic targets. However, current standard of 
anti-viral therapy has been the combination of pegylated interferon-α with 
ribavirin (Peg-IFN/RBV), until a recent addition of the HCV protease inhibitors 
such as Boceprevier and Telaprevir. However, even with the protease inhibitors, 
sustained virologic response (SVR) for genotype 1 is still about 60~80%. 
Therefore development of effective anti-HCV drug candidates is urgently 
needed. In this chapter, we report the discovery of a series of extremely potent 
HCV NS5A inhibitors based on the symmetrical benzidine and fluorine 
prolinamide skeleton. Taking a simple synthetic route, we established a library 
of novel potent HCV NS5A inhibitor flatform, which allows easy modification, 
and through optimization of the diversity of the region, we identified some 
compounds exhibiting highly potent anti-HCV activities. Furthermore, through 
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a battery of studies including hERG ligand binding assay, CYP450 binding assay, 
rat plasma stability test, human liver microsomal stability test, and 
pharmacokinetic studies, the identified some compounds are found to be 
nontoxic, and are expected to be effective therapeutic anti-HCV agents. 
 
Key words: HCV, NS5A inhibitor, Antiviral agent, Benzidine, 
Diaminofluorene, Structure-activity relationship 
 
*Part I of this thesis was published in ACS Med. Chem. Lett. 2014, 5, 255−258, 
and Eur. J. Med. Chem. 2015, 101, 163-178. 
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Part II. Synthesis of conjugated polymers using 
palladium iron oxide nanocrystals† 
 
Conjugated polymers (CP) have attracted much interest in academic and 
industrial fields due to their electrical and optoelectronic properties. Most of 
CP’s have been synthesized via metal-catalyzed reactions in homogeneous 
system such as Pd-catalyzed Suzuki, Stille, Heck, Sonogashira reactions, Ni-
catalyzed Negishi, Kumada reactions, Ru-catalyzed olefin metathesis reactions 
(ROMP, ADMET), and Cu-catalyzed Huisgen 1,3-dipolar cycloaddition 
reaction. However, these homogeneous systems are mostly limited in that 
catalysts always remain within the CPs as ligands and metal after the reaction. 
These residual catalysts could reduce the electrical performance of CP, because 
those residual catalysts could act as a trap site of a hole or an electron. In this 
chapter, we report on the utilization of Pd-Fe3O4 heterodimer nanocrystals 
(HNCs) as a magnetically recyclable and effective catalyst for the repetitive 
synthesis of CP via Suzuki cross-coupling reactions. After optimization of 
various reaction conditions of the polymerization, it was found that Pd-Fe3O4 
heterodimer nanocrystals exhibit good catalytic activity for the synthesis of 
CP’s, can minimize the Pd content in the product CP, was magnetically 
recoverable through external magnet, and finally was reusable for the 
polymerization eleven times. Moreover, these nanocrystals have a relatively 
uniform size and are dispersed evenly throughout the reaction media. This 
iv 
 
synthetic method can possibly take us one step closer to the green synthesis of 
CPs. 
 
Key words: Heterodimeric nanocrystals, palladium nanoparticle, Pd-Fe3O4, 
Suzuki polycondensation, catalyst, magnetic separation, recycling 
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Studies on the potent hepatitis C 
virus NS5A inhibitors 
 
Chapter 1. Development of potent hepatitis 










Approximately 170 million people, including almost 4 million in the United 
States, are estimated to be infected with hepatitis C virus (HCV).1,2 It has been 
estimated that 75-85% of those infected with HCV will develop chronic 
hepatitis and more serious diseases such as liver cirrhosis and hepatocellular 
carcinoma.3 Until recently, therapies for HCV patients have consisted of 
subcutaneous injections of pegylated interferon-α (PEG-IFN-α) in combination 
with oral doses of ribavirin (RBV).4 This interferon based therapy has a limited 
sustained virologic response (SVR), especially in patients infected with 
genotype 1 HCV. In 2011, the US Food and Drug Administration (FDA) 
approved Boceprevir (Merck) and Telaprevir (Vertex Pharmaceuticals and 
Johnson & Johnson) as antiviral agents directly targeted against HCV NS3/4A 
protease, in combination with PEG-IFN-α and RBV. In genotype 1 patients, 
very promising results have been reported when either Telaprevir or Boceprevir 
are added to the standard of care.5 Although the introduction of these direct-
acting antivirals (DAAs) into the regimen improves therapeutic outcome, their 
possible limitations include a low genetic barrier, which may result in the 
appearance of drug-resistant mutants during long-term treatment. The 
development of effective and safe small molecule antiviral agents aimed at a 
variety of gene targets was therefore warranted.6 
HCV, which belongs to the Hepacivirus genus in the Flaviviridae family, 
contains a 9.8 kb, single-stranded positive sense RNA genome encoding a 
polyprotein of approximately 3,000 amino acids. This polyprotein encompasses 
structural proteins (Core, E1 and E2), virion particles and nonstructural proteins 
(NS2, NS3, NS4A, NS4B, NS5A and NS5B) participating in RNA replication.7-
9 Although the precise enzymatic role of NS5A has not been clarified, it has 
been shown to be essential for HCV replication, virus assembly, and the host 
immune response related to viral resistance to IFN-α therapy. NS5A is zinc-
binding phosphoprotein (56-58 kDa), consisting of 447 amino acids,10,11 and 
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associated with the membrane through an N-terminal amphipathic α-helix 
region.12 The three principle domains in NS5A are domain I, containing a zinc 
binding motif required for viral RNA replication;13 domain II, which interacts 
with NS5B and cellular proteins such as PKR and PI3K, and domain III, which 





















A novel NS5A inhibitor, daclatasvir (1, shown above; BMS-790052, 
combination therapy with sofosbuvir approved by Daklinza in 2015), was 
recently reported to exhibit strong anti-HCV activity, particularly in the case of 
the HCV genotype 1. The effective concentration (EC50) of daclatasvir was 
shown to be in the picomolar range in vitro and, in clinical trials, a single dose 
treatment of 100 mg reduced HCV RNA level about 3.3log10 without apparent 
toxicity.15,16 Subsequently, pharmaceutical companies and numerous research 
groups have focused on the development of a series of NS5A inhibitors.17-21 For 
instance, Merck reported the elbasvir (combination therapy with grazoprevir 
approved by Zepatier in 2016), Abbvie pharmaceutical research & development 
reported ombitasvir (combination therapy of paritaprevir and ritonavir 
approved by Viekira Pak in 2014), and ledipasvir (combination therapy with 
sofosbuvir approved by Harvoni in 2014) was developed by the Gilead 
Sciences. In addition to thesis efforts , currently known candidates in this series 
include GS-5885, ABT-267, PPI-461, AZD-7295, BMS-824393, ACH-2928, 
IDX-719, PPI-1301, and EDP-239.22 Daclatasvir (1) has a biphenyl core 
connected to an imidazole moiety, a proline moiety, and a capping group of 
amino acid derivatives. In 2012, Schinazi and co-workers reported new 
inhibitors containing a variety of extended biphenyl linkers with small 
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modifications at both ends of the inhibitors.23-25 Here, we report a new class of 




2. Result and Discussion 
 
The symmetrical structure of the benzidine scaffold greatly simplified our 
synthetic route. Coupling of Boc-L-proline with benzidine resulted in excellent 
yield of an almost pure product, obviating the need for column chromatographic 
purification. After removal of the Boc group using trifluoroacetic acid (TFA) 
in CH2Cl2, a series of capping groups was added to the free amine using either 
peptide coupling (EDCI and Hünig’s base in CH2Cl2) or reductive amination, 




















Scheme I-1. Synthesis of benzidine prolinamide skeletona 
aReagents and conditions: (a) N-Boc-L-Proline, EDC, DCM, 94%; (b) TFA, 
DCM; (c) Capping Group, EDC, DIPEA, DCM 22-49% (2 steps). 
 
To determine the inhibitory activities (EC50’s) of the compounds, dose-
response experiments were performed using an infectious HCV cell culture 
system (HCVcc). JFH 5a-Rluc-ad34 is a derivative of JFH1 containing a 
Renilla luciferase reporter and cell culture adaptive mutations.28 Huh 7.5.1 cells 
were inoculated with the HCVcc for 3 h and then cultivated for 3 d in the 
presence of the indicated compounds at serially diluted concentrations. After 
cell harvesting, EC50’s were calculated by sigma plot analysis of the luciferase 
activities in the cells. 
12 
 
The assay data indicate that the inhibitory activity of these compounds is 
greatly dependent upon the structure of the flanking end groups (Table I-1).29,30 
When both enantiomers of N-methyloxycarbonyl-protected valine were 
attached, a clear difference in inhibitory activity between the two epimers was 
observed, indicating the importance of the stereochemistry of the capping group. 
The inhibitory activity of the D-isomer (compound 4) was 8 fold higher than 
that of the L-epimer (compound 5, Table I-1, entries 1 and 2, respectively). Next, 
we identified the optimal capping group through a series of structure-activity 
relationship (SAR) studies. When phenylglycine derivatives were incorporated 
on both ends, extremely high inhibitory activities were observed, regardless of 
the N-protecting groups. The highest inhibition was observed for the compound 
containing an N-methyloxycarbonylphenylglycine group (compound 6, Table 
I-1, entry 3), while N,N-dimethylamino- and N,N-diethylamino-protected 
phenylglycine derivatives also had inhibitory EC50’s in the low nanomolar 
range. Compounds 6-8 were potent inhibitors of HCV proliferation, with EC50’s 
of 260 pM, 2.3 nM, and 2.2 nM in infectious HCVcc, respectively, and none 
had detectable cytotoxic effects at 25 µM of concentration (Table I-1, entries 
3-5, respectively). In contrast, compound 9 which contains a N-
methyloxycarbonyl-L-alanine moiety, had no detectable inhibition at 1 µM. 
Inhibitors capped with N-methyloxycarbonyl-L-tert-leucine and N-2(R)-
tetrahydrofurylcarbonyl groups inhibited HCV proliferation with EC50’s of 24 





Table I-1. Structure-Activity-Relationships of inhibitors containing a 
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To assess the inhibitory activity of compounds on HCV replication, we 
measured EC50’s using a HCV replicon containing a HCV non-structural 
protein, NS3-NS5B, and the Renilla luciferase reporter gene.31,32 Compound 6 
showed the highest inhibition in the replicon assay (EC50 = 28 pM), while 
compounds 7 (EC50 = 0.43 nM) and 8 (EC50 = 0.27 nM) also exhibited 
subnanomolar inhibition (Table I-2, entries 1-3). 
 








1 6 0.028 nM >25 µM >893 
2 7 0.43 nM >25 µM >58 
3 8 0.27 nM >25 µM >93 
 
Since compound 6 exhibited the highest inhibitory activity both in HCVcc 
infection (Table I-1, entry 3) and in the replicon system (Table I-2, entry 1), we 
next focused our attention on further evaluation of this compound.33 
First, to evaluate the potential cardiac toxicity of compound 6 through 
inhibition of the inward rectifying voltage gated potassium channel encoded by 
the hERG gene, we carried out a hERG assay.34,35 Compared to the astemizole 
control (EC50 = 1.9 nM), compound 6 (EC50 = 9.8 µM) was shown to bind 
poorly to the hERG membrane preparations, suggesting that compound 6 would 





Table I-3. hERG Ligand Binding Assay 
Compound % Inhibition (uM) 
6 9.8 
Control (Astemizole) 0.0019 
 
Next, a rat plasma stability test36,37 of compound 6 (Table I-4) showed that 
more than 99% of the compound was intact after 4 h, indicating high in vivo 
stability (Table I-4). 
 
Table I-4. Stability of compound 6 in rat plasma 
Compound 6 (2 µM) 0.5 h (%) 1 h (%) 4 h (%) 
6 >99 >99 >99 
 
Next, to evaluate potential drug-drug interactions of compound 6, we carried 
out CYP450 screening (Table I-5).38 A compound exhibiting greater than 50% 
inhibition of CYP450 activity at a concentration of 10 µM is classified as a 
CYP450 enzyme inhibitor. CYP1A2 (18.12% inhibition) and CYP3A4 (23.87% 
inhibition) were weakly inhibited in the presence of 10 µM compound 6, while 
CYP2C9 and CYP2D6 retained maximal activity under the same conditions. 
We conclude that compound 6 does not significantly inhibit these four 





Table I-5. CYP450 screening assay 
Compound 1A2 2C9 2D6 3A4 
6a 18.12 0 0 23.87 
Inhibitorb 98.60 75.79 95.07 95.34 
aCYP inhibition (%) of Compound 6 at 10 µM.  
b1A2: α-naphthoflavone, 2C9: sulfaphenazole, 2D6: quinidine, 
3A4:ketoconazole 
 
To determine whether compound 6 would have a synergistic or additive anti-
HCV effect in combination with sofosbuvir therapy, we treated replicon with 
compound 6 in the presence of a 125 nM of concentrations of sofosbuvir39,40 
and monitored the effect on HCV proliferation (Figure I-1). Our data show that 
compound 6 and sofosbuvir have a distinct additive effect on the proliferation 
of HCV, presumably due to the independent modes of action of compound 6 
and sofosbuvir. 
 
Figure I-1. Effect of co-treatment of compound 6 and sofosbuvir on HCV 






In summary, we have developed a series of inhibitors based on a new 
benzidine prolinamide core structure, several of which have extremely high 
anti-HCV activity. SAR studies using a variety of terminal capping groups 
showed particularly high inhibitory activities for inhibitors containing phenyl 
glycine capping groups, of which compound 6 was the most potent. Moreover, 
subsequent studies demonstrated that compound 6 has a desirable cardiac 
toxicity, rat plasma stability, and drug-drug interaction properties. Our data 
indicate that compound 6 is a potent, safe lead compound that warrants further 







The 1H and 13C NMR-spectra were measured with a Bruker DPX-300 (300 
MHz), an Agilent 400-MR DD2 Magnetic Resonance System (400 MHz) and 
a Varian/Oxford As-500 (500 MHz) spectrophotometer. Chemical shifts were 
measured as part per million (δ values) from tetramethylsilane as an internal 
standard at probe temperature in CDCl3 or DMSO-D6 for neutral compounds. 
Reactions that needed anhydrous conditions were carried out in flame-dried 
glassware under positive pressure of dry N2 using standard Schlenk line 
techniques. Evaporation of solvents was performed at reduced pressure using a 
rotary evaporator. TLC was performed using silica gel 60F254 coated on 
aluminum sheet (E. Merck, Art.5554). Chromatogram was visualized by UV-
lamp (Vilber Lournat, VL-4LC) and/or colorized with following solutions: (a) 
20% ethanolic phosphomolybdic acid (PMA) (b) potassium permanganate 
solution (c) 2% ninhydrin ethanolic solution. Column chromatography was 
performed on silica gel (Merck. 7734 or 9385 Kiesel gel 60), and eluent was 
mentioned in each procedure. A Thermo-Finnigan LTQ-Orbitrap instrument 
(Thermo Scientific, USA) equipped with Dionex U 3000 HPLC system was 
used Mass spectrometric analyses were performed using a ThermoFinnigan 
LTQ-Orbitrap ion trap mass spectrometer, with ESI interface. HPLC analyses 
were carried out on an HP1100 system Agilent (Santa Clara, CA, USA), 
composed of auto sampler, quaternary pump, photodiode array detector (DAD) 
and HP Chemstation software. The separation was carried out on a C18 Vydac 
218TP54 column 250 x 4.6 mm i.d. (5 µm particle size) with 0.1% TFA in 
water(A), acetonitrile(B), as a mobile phase at a flow rate of 1 mL/min at 20 °C. 
Method : 0% B(0 min), 100% B(10 min), 100% B(20 min), 0% B(22 min), 0% 
B(25 min). All materials were obtained from commercial supplier and used 
without further purification unless otherwise noted. 
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Preparation of compounds  
 







(S)-2-((methoxycarbonyl)amino)-3-methylbutanoic acid (Cap-1). Na2CO3 
(1.83 g, 17.2 mmol) was added to aq NaOH (33 mL of 1 M/H2O, 33 mmol) 
solution of L-valine (3.900 g, 33.29 mmol) and the resulting solution was 
cooled with ice-water bath. Methyl chloroformate (2.8 mL, 36.1 mmol) was 
added dropwise, the cooling bath was removed and the reation mixture was 
stirred at ambient temperature for 3.25 h. The reaction mixture was washed with 
ether (3x17 mL), and the aqueous phase was cooled with ice-water bath and 
acidified with conc HCl to a pH region of 1-2, and extracted with CH2Cl2 (3x17 
mL). The organic phase was dried (MgSO4), filtered, and concentrated in vacuo 
to afford Cap-1 as a white solid (5.00 g, 86%) 1H NMR (DMSO-d6, δ=2.5 ppm, 
400 MHz): 12.51 (br s, 1H), 7.32 (d, 1H), 3.84 (t, 1H), 3.54 (s, 3H), 2.03 (m, 







(R)-2-((methoxycarbonyl)amino)-3-methylbutanoic acid (Cap-2). Yield 760 
mg (87%). 1H NMR (DMSO-d6, δ=2.5 ppm, 300 MHz): 12.54 (s, 1H), 7.32 (d, 











(R)-2-((methoxycarbonyl)amino)-2-phenylacetic acid (Cap-3). Na2CO3 (0.55 
g, 5.2 mmol) was added to aq NaOH (10 mL of 1 M/H2O, 10 mmol) solution 
of D-Phenylglycine (1.500 g, 10.0 mmol) and the resulting solution was cooled 
with ice-water bath. Methyl chloroformate (0.85 mL, 11.0 mmol) was added 
dropwise, the cooling bath was removed and the reation mixture was stirred at 
ambient temperature for 3.25 h. The reaction mixture was washed with ether 
(3x18 mL), and the aqueous phase was cooled with ice-water bath and acidified 
with conc HCl to a pH region of 1-2, and extracted with CH2Cl2 (3x18mL). The 
organic phase was dried (MgSO4), filtered, and concentrated in vacuo, and the 
resulting oil residue was treated with diethyl ether/hexanes (~5:4 ratio; 10 mL) 
to provide a precipitate. The precipitate was filtered and washed with diethyl 
ether/hexanes (~1:3 ratio) and dried in vacuo to provide Cap-3 as a fluffy white 
solid (1.4 g, 67%). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 12.79 (br s, 






(R)-2-(dimethylamino)-2-phenylacetic acid (Cap-4). A suspension of 10% 
Pd/C (310 mg, 0.3 mmol) in methanol (1.5 mL) was added to a mixture of D-
Phenylglycine (1.51 g, 10 mmol), formaldehyde (5 mL of 37% wt. in water), 1 
N HCl (4.5 mL) and methanol (4.5 mL), and stirred under H2 atmosphere 
(balloon) overnight. The reaction mixture was filtered through Celite, and the 
filtrate was concentrated in vacuo. The resulting crude material was 
recrystallized from isopropanol to provide an HCl salt of Cap-4 as a white 
needle (1.84 g, 89%). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 7.43-7.39 








(R)-2-(diethylamino)-2-phenylacetic acid (Cap-5). NaBH3CN (786 mg, 12.5 
mmol) was added in portions over a few minutes to a cooled (ice/water) mixture 
of D-Phenylglycine (756 mg, 5.00 mmol) and methanol (13 mL), and the 
mixture was stirred for 5 min. To the mixture was added acetaldehyde (1.3 mL, 
22.5 mmol) dropwise and stirring was continued at the same cooled temperature 
for for 45 min and at ambient temperature for another ~6.5 h. The reaction 
mixture was cooled with ice-water bath, quenched with a dropwise addition of 
conc HCl until the pH of the mixture was 1.5-2.0. The reaction mixture was 
stirred overnight, filtered to remove the white suspension, and the filtrate was 
concentrated in vacuo. The crude material was recrystallized from ethanol to 
afford the HCl salt of Cap-5 as a shining white solid (625 mg, 60%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 500 MHz): 10.77 (br s, 1H), 7.72 (m, 2H), 7.51 (m, 









(S)-2-((methoxycarbonyl)amino)propanoic acid (Cap-6). Na2CO3 (0.55 g, 5.2 
mmol) was added to aq NaOH (10 mL of 1 M solution, 10 mmol) solution of 
L-alanine (0.890 g, 10.0 mmol) and the resulting solution was cooled with ice-
water bath. To the mixture was added methyl chloroformate (0.85 mL, 11.0 
mmol) dropwise, the cooling bath was removed and the reation mixture was 
stirred at ambient temperature for 3.25 h. The reaction mixture was washed with 
ether (3x18 mL), and the aqueous phase was cooled with ice-water bath and 
acidified with conc HCl to a pH region of 1-2, and extracted with CH2Cl2 
(3x18mL). The organic phase was dried (MgSO4), filtered, and concentrated in 
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vacuo to afford Cap-6 as a colorless viscous oil (0.83 g, 56%). 1H NMR (CDCl3, 
δ=7.26 ppm, 500 MHz): 10.00 (br s, 1H), 5.49 (d, J=12, 1H), 4.38 (m, 1H), 3.69 









(S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanoic acid (Cap-7). Yield 
670 mg (71%). 1H NMR (CDCl3, δ=7.26 ppm, 500 MHz): 9.57 (br s, 1H), 5.31 
(d, 1H), 4.20 (d, 1H), 3.70 (s, 3H), 1.03 (s, 9H). 
 














diylbis(azanediyl))bis(oxomethylene)dipyrrolidine-1-carboxylate (2). A 
mixture of N-Boc-L-proline (8.00 g, 86.3 mmol), EDC (19.0 g, 99.0 mmol), 
and benzidine (7.00 g, 38.0 mmol) in CH2Cl2 (38 mL) was stirred at ambient 
temperature for 2 h. The resulting residue was partitioned between CH2Cl2 and 
H2O. The organic layer was washed with 1 N aq HCl solution and brine, dried 
MgSO4, filtered, and concentrated in vacuo. Without any purification, 2 was 
obtained as a brown solid (20.7 g, 94%). 1H NMR (DMSO-d6, δ=2.5 ppm, 300 
MHz): 10.06 (s, 2H), 7.69-7.59 (dd, 8H), 4.24 (m, 2H), 3.39 (m, 4H), 2.21 (m, 
2H), 1.85 (m, 6H), 1.41-1.28 (app br s, 18H). 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): 171.5, 153.2, 138.2, 134.5, 126.4, 119.6, 78.5, 60.4, 46.6, 31.0, 
28.1, 28.0, 23.4. LC/MS: Anal. Calcd. For [M+H]+ C32H42N4O6:579.3177; 
found 579.3152. 
 













oxobutane-2,1-diyl))dicarbamate (4). A mixture of biphenyl 2 (138 mg, 0.238 
mmol) in CF3CO2H (1 mL) and CH2Cl2 (1 mL) was stirred at room temperature 
for 5 h. The volatile component was removed in vacuo, EDC (119 mg, 0.620 
mmol), Cap-2 (100 mg, 0.572mmol) was added in batches over 4 min to a 
solution of i-Pr2NEt (208 µL, 1.192 mmol) in CH2Cl2 (1 mL) and the reaction 
mixture was stirred at room temperature for 75 min. The residue was partitioned 
between CH2Cl2 and H2O. The organic layer was washed with H2O and brine, 
dried over MgSO4, filtered, and concentrated in vacuo. A silica gel mesh was 
prepared from the residue and submitted to flash chromatography (silica gel: 
EtOAc/hexane as eluent) to provide 4 as a white solid (69 mg, 42%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): 10.11 (s, 2H), 7.67-7.58 (dd, 8H), 7.32 (d, 
2H), 4.48 (m, 2H), 4.05 (t, 2H), 3.83 (m, 2H), 3.64 (m, 2H), 3.54 (s, 6H), 2.18 
(m, 2H), 1.94 (m, 8H), 0.96 (d, 6H), 0.90 (d, 6H). 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): 170.4, 170.4, 156.8, 138.3, 134.3, 126.4, 119.4, 60.2, 
58.0, 51.4 47.2, 29.9, 29.5, 24.7, 18.9, 18.6. LC/MS: Anal. Calcd. For [M+H]+ 













oxobutane-2,1-diyl))dicarbamate (5). Yield 60 mg (36%). 1H NMR (DMSO-d6, 
δ=2.5 ppm, 400MHz): 10.07 (s, 2H), 7.63-7.54 (dd, 8H), 7.31 (d, 2H), 4.43 (m, 
2H), 4.01 (t, 2H), 3.80 (m, 2H), 3.61 (m, 2H), 3.5 (s, 6H), 2.13 (m, 2H), 1.89 
(m, 8H), 0.92 (d, 6H), 0.86 (d, 6H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): 170.4, 170.4, 156.8, 138.3, 134.3, 126.4, 119.3, 60.2, 58.0, 51.4, 47.2, 
29.9, 29.5, 24.7, 18.9, 18.6. LC/MS: Anal. Calcd. For [M+H]+ 












phenylethane-2,1-diyl))dicarbamate (6). Yield 53 mg (46%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): 9.95 (s, 2H), 7.74-7.58 (m, 9H), 7.51-7.30 
(m, 10H), 7.14 (app br s, 1H), 5.51 (d, 2H), 4.42 (app br d, 2H), 3.83 (app br s, 
25 
 
2H), 3.55 (s, 6H), 3.20 (app br d, 2H), 2.04-1.79 (m, 8H). 13C NMR (DMSO-
d6, δ=39.52 ppm, 100 MHz): 170.2, 168.4, 156.1, 138.1, 137.2, 134.4, 128.6, 
128.0, 127.8, 126.4, 119.6, 60.7, 56.7, 51.6, 46.9, 29.3, 24.3. LC/MS: Anal. 












phenylacetyl)pyrrolidine-2-carboxamide) (7). Yield 40 mg (25%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400MHz): 10.09 (s, 2H), 7.68-7.60 (dd, 8H), 7.46-7.29 
(m, 10H), 4.37 (m, 2H), 4.21 (s, 2H), 3.87 (m, 2H), 3.45 (m, 2H), 2.16 (s, 12H), 
2.16-1.97 (m, 2H), 1.90-1.80 (m, 2H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): 170.5, 169.1, 138.3, 134.3, 129.1, 129.0, 128.2, 127.9, 126.4, 119.4, 
71.4, 60.6, 47.2, 42.9, 29.2, 24.5. LC/MS: Anal. Calcd. For [M+H]+ 














phenylacetyl)pyrrolidine-2-carboxamide) (8). Yield 34 mg (22%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400MHz): 10.08 (s, 2H), 7.68-7.60 (dd, 8H), 7.43-7.26 
(m, 10H), 4.70 (s, 2H), 4.43 (m, 2H), 3.81 (m, 2H), 3.39 (q, 2H), 2.67-2.59 (m, 
4H), 2.54-2.45 (m, 4H), 2.11-1.97 (m, 4H), 1.89-1.78 (m, 4H), 0.91 (t, 12H). 
13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 170.5, 169.8, 138.3, 137.5, 
134.3, 129.1, 128.1, 127.5, 126.4, 119.4, 66.2, 60.5, 47.1, 43.2, 29.2, 24.6, 12.6. 












2,1-diyl))dicarbamate (9). Yield 69 mg (47%). 1H NMR (DMSO-d6, δ=2.5 ppm, 
400MHz): 10.00 (s, 2H), 7.63-7.55 (dd, 8H), 7.32 (d, 2H), 4.43 (m, 2H), 4.30 
(t, 2H), 3.65 (m, 2H), 3.58 (m, 2H), 3.49 (s, 6H), 2.14 (m, 2H), 1.96 (m, 6H), 
1.18 (d, 6H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 171.3, 170.8, 
156.7, 138.6, 134.7, 126.7, 119.8, 60.6, 51.7, 48.4, 47.1, 29.7, 25.1, 17.2. 














oxobutane-2,1-diyl))dicarbamate (10). Yield 38 mg (24%). 1H NMR (DMSO-
d6, δ=2.5 ppm, 400MHz): 10.11 (s, 2H), 7.66-7.57 (dd, 8H), 7.09 (d, 2H), 4.48 
(m, 2H), 4.23 (d, 2H), 3.79 (m, 2H), 3.63 (m, 2H), 3.54 (s, 6H), 2.18 (m, 2H), 
2.00 (m, 2H), 1.89 (m, 4H), 0.98 (s, 18H). 13C NMR (DMSO-d6, δ=39.52 ppm, 
100 MHz): 170.4, 169.6, 156.9, 138.3, 134.3, 126.4, 119.3, 60.2, 59.1, 51.5, 
47.9, 34.5, 29.5, 26.4, 24.8. LC/MS: Anal. Calcd. For [M+H]+ 












carbonyl)pyrrolidine-2-carboxamide) (11). Yield 101 mg (49%). 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400MHz): 10.21 (s, 2Htrans or 2Hcis), 10.05 (s, 2Htrans or 
2Hcis), 7.67-7.59 (dd, 8H), 4.79 (d, 2Htrans or 2Hcis), 4.58 (t, 2Htrans or 2Hcis), 4.42 
(d, 2Htrans or 2Hcis),  4.30 (t, 2Htrans or 2Hcis), 3.83-3.68 (m, 5Htrans/5Hcis), 3.58-
28 
 
3.37 (m, 3Htrans/3Hcis), 2.13-1.75 (m, 16Htrans/16Hcis). 13C NMR (DMSO-d6, 
δ=39.52 ppm, 400 MHz): 170.78, 170.52, 170.29, 170.13, 138.2, 134.3, 126.50, 
126.43, 126.38, 126.31, 119.77, 119.44, 76.22, 76.08, 68.38, 68.18, 60.37, 
59.77, 46.99, 46.62, 32.1, 29.2, 28.2, 25.32, 25.05, 24.6, 21.8. LC/MS: Anal. 










Chapter 2. New series of benzidine and 
diaminofluorene prolinamide derivatives as 








In 2010, a landmark NS5A inhibitor, daclatasvir (1), was reported to 
present excellent anti-HCV activity, especially in patients with HCV G-
1 infection. This new class of inhibitor was approved Daklinza by the US 
FDA in 2015.15,41-44 The effective concentration (EC50) value of 
daclatasvir was two-digit picomolar (pM) range in in vitro assay, and 
treatment with a single 100 mg dose in clinical trials reduced HCV RNA 
levels by an average of 3.3log10 without apparent toxicity.45 This result 
stimulated numerous research groups and pharmaceutical companies to 
focus on the development of new inhibitors targeting NS5A.17,19-22,46-50 
Currently, there are many candidate compounds in this series: ABT-267, 
ACH-2928, ACH-3102, AZD-7295, BMS-346, BMS-665, BMS-824393, 
EDP-239, GS-5885, GSK-2336805, IDX-719, MK-4882, MK-8742, 
PPI-461, and PPI-1301 (Figure I-2).51-58 Most recently, interferon-free 
multi-class drug combinations (daclatasvir and asunaprevier, Harvoni®, 
and Viekira Pak®) are viewed as the optimal therapy.59 The structure of 
daclatasvir is characterized by a central biaryl core unit linked to an 
imidazole and proline moiety, and lastly, a methyl carbamate L-valine 
moiety as a capping group (Figure I-3).23 In 2012, Schinazi et al. reported 
nascent NS5A inhibitors containing a part of biaryl core and some 
modifications on other parts through “Click” and C-C bond cross 
coupling reactions.24,25 We recently developed a new class of NS5A 
inhibitors represented by BMK-20113, which has benzidine (i) and L-
proline (ii) connected as an amide functionality and a variety of capping 
groups (iii).60 In this paper, we report improvements in antiviral potency 
through the introduction of new modifications to the backbone of BMK-
31 
 
20113: L-proline to other proline isosteres (area ii in Figure I-3), and 



















































































































2. Result and Discussion 
 
The symmetry in the benzidine-proline scaffold greatly streamlined our 
strategy of synthesizing BMK-20113. Initially, we wanted to evaluate the 
antiviral activity of the proline variation; therefore, L-proline isosteres were 
employed, such as D-proline, 4-oxo-L-proline, L-thioproline, L-pipecolic acid, 
D-pipecolic acid, and α-methyl-L-proline, by using the standard peptide 
coupling protocol of EDCI in DCM. After purification of intermediates 2-8 
through chromatographic columns, the Boc protected secondary amine site was 
removed with diluted trifluoroacetic acid (TFA) in DCM.61 Then methyl 
carbamate phenylglycine 9 was coupled with the free amine with the aid of 
EDCI and DIPEA in DCM. In cases where solubility was a persistent problem, 
we used DMF as a solvent.26,27 The targeted benzidine proline derivatives 10-











































Scheme I-2. Synthesis of benzidine and proline derivatives from an amide 
skeletona 
aReagents and conditions: (a) N-Boc-proline derivatives, EDCI, DCM, 31-99%; 
(b) TFA, DCM; (c) 9 (Capping Group), EDCI, DIPEA, DCM or DMF, 13-57% 
(2 steps). 
 
Next, structure-activity relationship studies centered on the benzidine core by 
employing various substituted benzidine compounds were carried out using o- 
or m-substituted benzidine derivatives (o-methyl, m-methyl, m-trifluoromethyl, 
m-fluoro, m-chloro, and m-bromo). After a coupling reaction, almost pure N-
Boc-protected prolinamide products 17-22 were obtained in excellent yields 
(92-97%). Using the same method described above, capping groups were 
incorporated and the final products 23-28 were obtained in low to good yields 
(32-73%) (Scheme I-3). 
  Proline Derivatives 
2 10 L-Proline 
3 11 D-Proline 
4 12 4-Oxo-L-proline 
5 13 L-Thioproline 
6 14 L-Pipecolic acid 
7 15 D-Pipecolic acid 






































Scheme I-3. Synthesis of benzidine derivatives and prolinamide skeletona 
aReagents and conditions: (a) N-Boc-L-Proline, EDCI, DCM, 92-97%; (b) TFA, 
DCM; (c) 9 (capping group), EDCI, DIPEA, DCM, 32-73% (2 steps). 
 
For the construction of the fluorene derivative core structures, we first needed 
to synthesize 2,7-diaminofluorene derivatives (Scheme I-4). After the treatment 
of 2,7-dinitrofluorene with 1.00 M LiHMDS followed by N-
fluorobenzenesulfonimide (NFSI) in THF, we obtained 9,9-difluoro-2,7-
dinitro-9H-fluorene 30 in 86% yield. Dimethyl derivative was synthesized 
likewise, treating 2,7-dinitrofluorene with NaOt-Bu followed by iodomethane 
in DMF to furnish the desired 9,9-dimethyl-2,7-dinitro-9H-fluorene 31 with an 
80% yield.62 The nitro groups of both 30 and 31 were efficiently reduced to 
amino functionality per our recent report on commercially available Fe3O4 
  R1 R2 
17 23 H CH3 
18 24 CH3 H 
19 25 CF3 H 
20 26 F H 
21 27 Cl H 
22 28 Br H 
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nanoparticles as a heterogeneous catalyst for nitro group reduction in 
combination with hydrazine monohydrate.63 Extremely high yields (99%) of 
the desired diamino compounds 32 and 33 were obtained. Moreover, a 
reasonable yield (76%) of the diamino ketone compound 35 was obtained by 
oxidizing the 9H-fluorene-2,7-diamine in the presence of a strong base (Cs2CO3) 
in DMSO in open air.64 
 























Scheme I-4. Synthesis of fluorene-2,7-diamine derivativesa 
aReagents and conditions: (a) N-fluorobenzenesulfonimide, LiHMDS in THF 
(1.00 M solution), THF, 86%; (b) iodomethane, NaOt-Bu, DMF, 80%; (c) 
Fe3O4, NH2NH2·H2O, DMF, 99%; (d) Cs2CO3, DMSO, 76%. 
 
After preparation of various 2,7-diaminofluorene derivatives, inhibitors 
containing L-proline and the capping group were prepared using the method 
described in Scheme I-2. N-Boc-protected fluorine prolinamides 36-39 were 
thus obtained in high yields (91-97%), obviating column chromatographic 
purification. Deprotected amines and coupling of the (R)-phenylglycine 
derivative gave us the desired fluorene derivatives 40-43 in moderate yields 
































Scheme I-5. Synthesis of fluorine-containing prolinamide derivativesa 
aReagents and conditions: (a) N-Boc-L-Proline, EDCI, DCM, 91-97%; (b) TFA, 







Table I-6. Structure-activity relationships of inhibitors containing various 











































































To determine the inhibitory activities (EC50 values) of each compounds, we 
used the HCV cell culture system (HCVcc) and HCV replicon system.32,65,66 To 
determine EC50 values in the HCVcc system (genotype 2a), we used a modified 
JFH1 clone (JFH 5a-Rluc-ad34) containing the Renilla luciferase gene (Rluc) 
in the NS5A region and cell culture adaptive mutations in the E2 and p7 
region.28 Huh7.5.1 cells were infected with JFH5a-Rluc-ad34 for 4 h. After 
infection, Huh7.5.1 cells were incubated with compounds of interest at various 
concentrations for 3 d. Then, the cells were harvested and luciferase activities 
were measured. We determined EC50 values using the HCV replicon system to 
evaluate the inhibitory activities of the synthesized compounds on HCV 
replication. HCV replicon systems (genotype 1b) containing HCV NS3-5B and 
the Renilla luciferase gene allow for productive viral RNA replication in cell 
culture systems. HCV replicon-containing cells were cultivated in the presence 
of serially diluted compounds for 3 d. Cells were harvested after treatment with 
chemicals for 3 d, and luciferase activities were measured. Luciferase activities 
were normalized to those obtained from mock-treated cells and EC50 values 
were calculated using a Sigma Plot analysis based on luciferase activities in the 
cells. The antiviral activities (EC50) of these compounds against the HCV GT-
2a and GT-1b are listed in Tables I-6, I-7, and I-8. 
The SAR data indicates that the inhibitory activities of these compounds are 
significantly dependent upon the structural feature of the proline derivatives 
(Table I-6). The EC50’s of our previously reported inhibitor containing L-proline, 
namely BMK-20113 (entry 1, compound 10), against GT-2a and GT-1b were 
reported to be 260 and 28 pM, respectively. The inhibitory activities of the D-
isomer 11 were 6,500-fold and 2,900-fold lower than those of the L-epimer, 
respectively, against the GT-2a and GT-1b genes (Table I-6, entry 2). 
Installation of a ketone at the 4-position of L-proline 12 resulted in a similar 
GT-2a inhibitory activity (EC50: 0.26 nM), and a slightly decreased GT-1b 
inhibitory activity (EC50: 0.044 nM) compared to those of the L-proline 
derivatives (Table I-6, entry 3). When L-thioproline was incorporated into the 
39 
 
benzidine 13, the activity was slightly decreased in GT-2a, but there was a 
similar potency in GT-1b (EC50 of GT-2a and GT-1b: 15.5 nM and 0.027 nM, 
respectively; Table I-6, entry 4). The inhibitor containing a six-membered L-
pipecolic acid moiety 14 showed lower activity than its five-membered ring 
counterpart (Table I-6, entry 5). The opposite stereoisomeric D-pipecolic acid 
derivative 15 exhibited an even more pronounced decrease in inhibitory 
activities (EC50 values all in the nanomolar range; Table I-6, entry 6). Lastly, 
the antiviral activities of the α-methyl substituted L-proline derivative 16 were 
lower than those of BMK-20113 (EC50 of GT-2a and GT-1b: 3.3 nM and 2.2 
















Table I-7. Structure-activity relationships of inhibitors containing substituted 
benzidine derivatives against HCV type 2a and type 1b. 








1 10 H H 0.26 0.028 >25 
2 23 H CH3 193 7.4 >25 
3 24 CF3 H 0.025 0.0025 >25 
4 25 CH3 H 0.32 0.035 >25 
5 26 F H 0.16 0.005 >25 
6 27 Cl H 0.01 0.007 >25 
7 28 Br H 0.01 0.007 >25 
 
Next, after fixing the L-proline and capping groups at both ends, we 
investigated the structure-activity relationship (SAR) studies of various 
40 
 
benzidine-containing derivatives by varying the middle biaryl portion (area i in 
Figure I-3). We first tested the o-methyl substituted benzidine derivative 23 for 
inhibitory effects and observed that low activities against the HCV (EC50 of GT-
2a and GT-1b: 193 nM and 7.4 nM, respectively; Table I-7, entry 2). However, 
a series of m-substituted benzidine derivatives 24-28 exhibited more enhanced 
inhibitory activities against HCV. In detail, the EC50 of CF3-substituted 
compound 24 in GT-2a and GT-1b were 25 and 2.5 pM, respectively (Table I-
7, entry 3), and the values for CH3-substituted compound 25 were 320 and 35 
pM, respectively (Table I-7, entry 4). After noticing the strong inhibitory effect 
of the meta-substituted compound, we decided to explore a heteroatom 
substitution in the m-position of the benzidine core.67-70 All three inhibitors 
containing m-fluoro-, m-chloro- and m-bromo-substituted benzidine cores 
(compounds 26, 27, and 28, respectively) exhibited powerful antiviral activities. 
EC50 values against GT-2a and GT-1b were 160 and 5 pM, respectively, for 
compound 26 (Table 2, entry 5) and 10 and 7 pM for compounds 27 and 28 
(entries 6 and 7, respectively).  
 
 
Figure I-4. Effect of compound 24 in combination with EC30 of NS5B 
polymerase inhibitor (sofosbuvir) on the HCV GT-1b replicon system. 




To see whether compound 24 has an additive or synergistic anti-viral effect in 
combination with an NS5B polymerase inhibitor (sofosbuvir), one of the top 10 
blockbuster drugs in 2014,6,71-74 we treated NK/R2AN replicon cells with 
serially diluted compound 24 in the presence of an EC30 concentration (123 nM) 
of sofosbuvir, and the luciferase activities in the cells were measured. Our data 
demonstrated that the combination therapy of compound 24 and sofosbuvir has 
a remarkably positive effect against HCV replicon cells, probably due to the 












(type 2a) (pM) 
Replicon EC50 




1 Isomer 1 332 27.9 >25 
2 Isomer 2 24.6 2.4 >25 
 
Since compound 24 contains a core structure that can exist as atropisomers, 
we were curious about the potentially different inhibitory activities of each 
isomer. The separation of racemic 2,2’-bis(trifluoromethyl)benzidine was 
successfully performed through the use of a chiral preparative column on 
supercritical fluid chromatography (SFC).79 Then, each isomer of compound 24 
was synthesized using each isomer from the separation following the method 
described in Scheme I-3. Its effect on HCV proliferation was measured. It was 
found that isomer 1 of compound 24 showed a 13-fold less potent anti-viral 
activity than isomer 2, which exhibited a similar activity to that of racemic 24 
(Table I-8, entries 1-2, and Table I-7, entry 3, respectively). Therefore, we 
















Table I-9. Structure-activity relationship studies of inhibitors containing a 
fluorene skeleton against HCV type 2a and type 1b. 









1 40 CH2 5.6 0.009 >25 
2 41 C=O 4.3 0.004 >25 
3 42 CMe2 0.020 0.004 >25 
4 43 CF2 0.059 0.003 >25 
 
When we tested the anti-viral activities of compounds 23-28, meta-
substitution of the benzidine prolinamides made the inhibitors highly potent 
HCV inhibitors. Therefore, we envisioned that the activity of m-,m-connected 
benzidine, i.e., fluorene derivatives would exhibit high potency in the antiviral 
assays. Based on the positive results of previously reported NS5A inhibitors 
containing a fluorenyl core structure,57 we synthesized and investigated 
inhibitors with a fluorenyl core. We were extremely pleased to observe that 
these inhibitors exhibited exceptionally high potencies, particularly in the 
replicon (GT-1b) assay (Table I-9, entries 1-4). Inhibitory activities (EC50) of 
compound 40 containing the parent fluorene were 5.6 and 9 pM against GT-2a 
and GT-1b, respectively (Table I-9, entry 1). The flurorenone-containing 
inhibitor 41 exhibited a similar potency to compound 40; EC50 of GT-2a and 
GT-1b were 4.3 and 4 pM, respectively (Table I-9, entry 2). Furthermore, 
substituents at the methylene position of the fluorene core showed a dramatic 
increase in anti-viral activity against the GT-2a gene.80 The inhibitory activity 
of compound 42 with a dimethyl-substituted fluorene moiety was 2,800-fold 
higher against the GT-2a gene than that of compound 40 containing the parent 
43 
 
fluorene (EC50 of GT-2a and GT-1b: 20 and 4 pM, respectively; Table I-9, entry 
3). Replacement of the dimethyl with difluorine 43 showed a similar effect 
(EC50 of GT-2a and GT-1b: 59 and 3 pM, respectively; Table I-9, entry 4).81 All 
of the inhibitors listed in Table I-6, Table I-7, Table I-8, and Table I-9 were not 
cytotoxic at 25 µM. 
 
Table I-10. Result of hERG ligand binding assaya 
Entry Compound Inhibition % (10 µM) 
1 24 7.98±4.49 
2 26 <1 
3 27 5.80±3.22 
4 42 25.7±4.90 
5 43 39.1±2.93 
6 Control (astemizole) 99.9 
aFluorescence polarization assay 
 
Since the compounds 24, 26, 27, 41, and 43 exhibited highly inhibitory 
activities both in the HCV GT-2a and the replicon (GT-1b) system (Table I-7, 
entries 3, 6, 7, and Table I-9, entries 3, 4, respectively), we next focused on 
further evaluation of these selected compounds.82 First, to evaluate any 
probable cardiac toxicity, we performed a hERG ligand binding assay, 
examining inhibition of the inner rectifying voltage-gated fluorescence 
polarization potassium ion channel which is encoded by hERG gene.34,83 
Compared to astemizole, which was used as a control (99.9% inhibition at 10 
µM), the values of compounds 24, 26, 27, 42, and 43 (7.98%, 1%, 5.80%, 
25.7%, 39.1% inhibition at 10 µM, respectively) suggested that these inhibitors 
bound poorly to the hERG membrane preparations, meaning minimal cardiac 





Table I-11. Stability in rat plasma (% remaining)  
Entry Compound 0.5 h (%) 1 h (%) 2 h (%) 
1 24 93 99 99 
2 26 65 61 63 
3 27 72 75 70 
 
Next, when the compounds were tested against rat plasma, our data showed a 
high in vitro stability for compound 24, which was unscathed after 2 hours (99% 
of the compound remained; Table I-11, entry 1), whereas after incubating for 
30 min, compounds 26 and 27 had degraded slightly (Table I-11, entries 2 and 
3). Consequently, it was necessary to carry out additional stability tests. 
 
Table I-12. Human liver microsomal stability (% remaining)  
Entry Compound 0.5 h (%) 
1 24 79 
2 26 97 
3 27 96 
4 42 95 
5 43 92 
 
In the human liver microsomal stability test, compound 24 was 21% digested 
in the plasma after 0.5 h (Table I-12, entry 1). Compounds 26, 27, 42, and 43 
had lower levels of degradation after 0.5 h (Table I-12, entries 2, 3, 4, and 5, 
respectively). These results indicate that these promising compounds had high 





Table I-13. EC50 of compounds (µM) against various subtypes of CYP450a 
Entry Compound 1A2 2C9 2D6 2C19 3A4 
1 24 78.8 0.660 >100 4.64 4.64 
2 26 >100 0.0877 4.94 0.724 2.46 
3 27 23.9 0.116 41.2 1.04 3.99 
5 42 >100 0.269 >100 2.94 1.03 
4 43 >100 0.277 >100 13.9 0.976 
a Standard inhibitors for each CYP450 subzymes: 1A2: α-naphthoflavone, 
2C9: sulfaphenazole, 2D6: quinidine, 2C19: miconazole 3A4: ketoconazole. 
 
Next, we outlined CYP450 inhibitory profiles to evaluate any drug-drug 
interactions possible with the selected compounds 24, 26, 27, 42, and 43. In 
general, high EC50 values for the CYP450 enzyme inhibitor indicate decreased 
liability for drug-drug interactions.38,85 Our selected compounds exhibited low 
inhibition profiles for various CYP450 isoforms. CYP1A2, CYP2D6, CYP2C19, 
and CYP3A4 were rather weakly inhibited in the presence of compounds 24, 
26, 27, 42, and 43, while the inhibition was higher for CYP2C9 (0.14, 0.0877, 
0.116, 0.269, and 0.277 µM respectively; Table I-13). However, there should 
still be a large safety margin when we compare these inhibitions to their anti-
viral activity.86 In summary, compounds 24, 26, 27, 42, and 43 do not 

















10 0.44±0.14 3.80±0.11 11.7 
2 26 10 0.11±0.07 2.34±0.37 3.12 
3 27 10 0.17±0.07 6.37±3.39 4.99 
5 42 10 0.98±0.02 4.45±4.02 13.8 
4 43 10 0.39±0.20 1.68±0.43 7.6 
6 24 
iv 
5 13.76±4.1 2.90±0.62  
7 26 5 16.63±2.57 0.88±0.34  
8 27 5 15.88±1.62 1.55±0.25  
10 42 5 13.26±1.13 1.62±0.78  
9 43 5 18.64±19.4 0.90±0.02  
a Vehicle : 5% DMSO/10% Solutol/85% HPBCD (20%, w/v), n = 3  
 
Studies on the pharmacokinetics (PK) of 5 selected compounds were carried 
out in rats, with the vehicles consisting of 5% DMSO, 10% solutol, and 85% 
(2-hydroxypropyl)-β-cyclodextrin (HPBCD) (Table I-14). Despite high 
potencies in in vitro studies of HCV inhibition, the selected compounds 
provoked some concern due to the symmetrical natures of their structures and 
their high molecular weights, which might lead to undesirable PK 
properties.33,88-93 Our data showed that the highest maximum concentration in 
plasma (Cmax) was obtained with compound 42 (0.98 μmol/mL) through oral 
administration, and compound 43 (18.64 μmol/mL) through intravenous 
administration (Table I-14, entries 5 and 9, respectively). The half-lives (t1/2) of 
these two compounds upon p.o. administration were 1.7 to 6.4 h, and in IV 
administration were 0.9 to 2.9 h, respectively. When we checked the oral 
bioavailability (F%), their low solubility and high lipophilicity contributed to a 







Figure I-5. Resistance profiles of inhibitors daclatasvir, 42, and 43. 
Measurements were carried out in triplicate. 
 
Then, we tested some of our selected inhibitors (42 and 43) against daclatasvir 
resistant mutants (L31V and Y93H) as described in Materials and Method.55 In 
vitro transcribed resistant mutant RNAs (L31V and Y93H) were individually 
transfected to Huh7.5.1 cells.96,97 After 4 h after transfection, the culture media 
were replaced with DMEM media containing serially diluted compounds. By 
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comparing the luciferase activities of 42 and 43 with those of daclatasvir, we 
concluded that 43 had a higher activity than 42 and a similar anti-viral potency 
to daclatasvir, to single mutant viruses. Therefore, we concluded that 43 could 
be a solution to the resistance problems of current HCV drugs (Figure I-5).  
 




VERO HFL-1 L929 NIH 3T3 CHO-K1 
43 >100 >100 >100 >100 >100 
a VERO: African green monkey kidney cell line; HFL-1: human embryonic 
lung cell line; L929: NCTC clone 929, mouse fibroblast cell line; NIH 3T3: 
mouse embryonic fibroblast cell line; CHO-K1: Chinese hamster ovary cell 
line. 
 
Then, we tested the cytotoxicity of compound 43 against some eukaryotic 
cells.98 The cell counting kit-8 assay method was used to measure the survival 
rate of the cells by using WST-8 tetrazolium salt. Hydrophilic WST-8 turns into 
orange formazan dye by dehydrogenase in cell lines. The number of living cells 
is determined by the activated dehydrogenase, which indicates the eukaryotic 
cell survival rate. At the maximal concentration (100 µM) used in the 
experiment, compound 43 showed less than 50% inhibition (the limit) in 
monkey kidney, human embryonic lung, mouse fibroblast, and hamster ovary 
cell line (Table I-15). Thus, we concluded that 43 is nontoxic and safe in the 











(Mean ± SD) [Factor]b 
Without S-9 
mix With S-9 mix 
TA-
98 
Vehicle control 0 18 ± 2 28 ± 3 
43 200 23 ± 5[1.3] 30 ± 2[1.1] 
TA-
100 
Vehicle control 0 117 ± 10 126 ± 19 
43 200 106 ± 3[0.9] 115 ± 8[0.9] 
 Positive control Dose (µg/plate) 
Without S-9 
mix With S-9 mix 
TA-
98 
2-Nitrofluorene 1 187 ± 
14[10.2] 
ND 
Benzo[a]pyrene 2 ND 171 ± 10[6.1] 
TA-
100 
Sodium azide 1 728 ± 15[6.2] ND 
Benzo[a]pyrene 2 ND 521 ± 28[4.1] 
a (Mean± SD, n = 3) 
b No. of revertant colonies in the treated plate/No. of revertant colonies in 
the vehicle control plate 
ND : Non Determined 
 
Next, we investigated the possibility that compound 43 might have genetic 
toxicity using the Ames test.99,100 For this purpose, we used Salmonella 
typhimurium strains TA-98 and TA-100 that require several amino acids for 
growth to test whether compound 43 functions as a mutagen. Growth of TA-98 
and TA-100 strains in the presence of the compound of interest in the media 
lacking histidine indicates that the compound is a potential mutagen inducing 
substitution, addition, and/or deletion of DNA. The result is considered to be 
positive when the number of colonies on the compound-treated plate increases 
double or more of those on the vehicle control plate. When we tested 200 
µg/plate of 43, the number of revertant colonies on the compound-treated plate 
was not increased compared with that on the vehicle-treated plate. And the 
number was much lower than those on 4 positive control compound-treated 





In conclusion, we developed a series of extremely potent HCV NS5A 
inhibitors using new benzidine and fluorene prolinamide derivatives as core 
structures. Several of them have highly potencies that produce inhibition even 
at the single digit pM level. Through the SAR studies using a variety of 
benzidine, proline, and fluorene derivatives with a phenyl glycine capping 
group, we were able to identify inhibitors possessing excessively high 
inhibitory activities. Among the new inhibitors, compounds 24, 26, 27, 42, and 
43 were the most potent. A synergistic effect with the NS5B polymerase 
inhibitor was seen with compound 24. Moreover, subsequent studies 
demonstrated that these compounds have a desirable low cardiac toxicity, high 
human microsomal stability, and limited drug-drug interactions. Compound 43 
was revealed to be non-toxic for eukaryotic cells and genetically non-toxic by 
the Ames test. The results of this study suggest that compound 43 is a highly 
potent and safe lead warranting further study as a potential HCV drug candidate. 
Further research on other pharmacological properties of the selected inhibitors 








The 1H and 13C NMR-spectra were measured with an Agilent 400-MR DD2 
Magnetic Resonance System (400 MHz) and a Varian/Oxford As-500 (500 
MHz) Spectrophotometer. The signals were reported as s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), or br s (broad singlet) and chemical shifts 
were measured as parts per million (δ values) from tetramethylsilane as an 
internal standard at probe temperature in CDCl3 or DMSO-D6 for neutral 
compounds. Reactions that needed anhydrous conditions were carried out in 
flame-dried glassware under a positive pressure of dry N2 using standard 
Schlenk line techniques. Evaporation of solvents was performed at reduced 
pressure using a rotary evaporator. TLC was performed using silica gel 60F254 
coated on an aluminum sheet (E. Merck, Art.5554). Chromatogram was 
visualized by UV-lamp (Vilber Lournat, VL-4LC) and/or colorized with 
following solutions: (a) 20% ethanolic phosphomolybdic acid (PMA), (b) 
potassium permanganate solution, and (c) 2% ninhydrin ethanolic solution. 
Column chromatography was performed on silica gel (Merck. 7734 or 9385 
Kiesel gel 60), and the eluent was mentioned in each procedure. High resolution 
mass spectra (HRMS) were recorded on a ThermoFinnigan LCQ™ Classic, 
Quadrupole Ion-Trap Mass Spectrometer. HPLC analyses were carried out on 
an Agilent HP1100 system (Santa Clara, CA, USA), composed of an auto 
sampler, quaternary pump, photodiode array detector (DAD), and HP 
Chemstation software. The separation was carried out on a C18 Vydac 218TP54 
column 250 x 4.6 mm i.d. (5 µm particle size) with 0.1% TFA in water (A), 
acetonitrile (B), as a mobile phase at a flow rate of 1 mL/min at 20 °C. Method: 
100% A and 0% B (0 min), 0% A and 100% B (10 min), 0% A and 100% B (20 
min), 100% A and 0% B (22 min), 100% A and 0% B (25 min). All materials 
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were purchased from a commercial supplier and used without further 
purification unless otherwise noted. 
 
Preparation of compounds  
 
(R)-2-((Methoxycarbonyl)amino)-2-phenylacetic acid (9). Na2CO3 (0.55 g, 
5.2 mmol) was added to an aq NaOH (10 mL of 1 M/H2O, 10 mmol) solution 
of D-phenylglycine (1.500 g, 10.0 mmol) and the resulting solution was cooled 
in an ice-water bath. Methyl chloroformate (0.85 mL, 11.0 mmol) was added 
dropwise, then the cooling bath was removed and the reaction mixture was 
stirred at ambient temperature for 3.25 h. The reaction mixture was washed with 
ether (3 x 18 mL), and the aqueous phase was cooled in an ice-water bath and 
acidified with conc. HCl to a pH range of 1-2, and extracted with CH2Cl2 (3 x 
18 mL). The organic phase was dried (MgSO4), filtered, and concentrated in 
vacuo, and the resulting oil residue was treated with diethyl ether/hexanes (~5:4 
ratio; 10 mL) to provide a precipitate. The precipitate was filtered and washed 
with diethyl ether/hexanes (~1:3 ratio) and dried in vacuo to provide 9 as a 
fluffy white solid (1.4 g, 67%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 500 MHz): 
12.79 (br s, 1H), 7.96 (d, J = 12, 1H), 7.40-7.29 (m, 5H), 5.13 (d, J = 12, 1H), 
3.55 (s, 3H). 
 
(2R,2'R)-Di-tert-butyl 2,2'-(([1,1'-biphenyl]-4,4'-
diylbis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (3). A mixture 
of N-Boc-D-proline (771 mg, 3.6 mmol), EDCI (812 mg, 4.2 mmol), and 
benzidine (300 mg, 1.63 mmol) in CH2Cl2 (4 mL) was stirred at ambient 
temperature for 2 h. The resulting residue was divided between CH2Cl2 and 
H2O. The organic soluble layer was washed with 1 N aq HCl solution and brine, 
dried over MgSO4, filtered, and concentrated in vacuo. Without any purification, 
17 was obtained as a solid (930 mg, 99%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 
400 MHz): 10.08 (s, 2H), 7.69-7.59 (dd, 8H), 4.29-4.20 (m, 2H), 3.44-3.35 (m, 
4H), 2.21 (m, 2H), 1.90-1.78 (m, 6H), 1.40-1.28 (app br s, 18H). 13C NMR 
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(DMSO-d6, δ = 39.52 ppm, 100 MHz): 171.5, 153.2, 138.2, 134.4, 126.4, 119.6, 
78.5, 60.4, 46.6, 31.0, 28.2, 28.0, 23.4. HRMS: Anal. calcd. for [M+H]+ 




Yield 320 mg (87%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.36 (d, 
2H), 7.65 (m, 8H), 4.78-6.49 (m, 2H), 3.89-3.76 (m, 4H), 3.11 (m, 2H), 2.57 
(m, 2H), 1.42-1.33 (app br s, 18H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 
MHz): 209.5, 208.9, 171.0, 170.7, 153.8, 153.4, 137.8, 134.8, 126.64, 126.58, 
119.7, 79.9, 79.8, 57.8, 57.0, 53.1, 41.5, 41.2, 28.1, 28.0. HRMS: Anal. calcd. 
for [M+H]+ C32H38N4O8: 607.2762; found 607.2756. 
 
(4R,4'R)-Di-tert-butyl 4,4'-(([1,1'-biphenyl]-4,4'-
diylbis(azanediyl))bis(carbonyl))bis(thiazolidine-3-carboxylate) (5). Yield 2.5 
g (64%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.15 (s, 2H), 7.68-7.61 
(dd, 8H), 4.72 (app br s, 1H), 4.63 (d, 2H), 4.55 (app br s, 1H), 4.45 (d, 2H), 
3.46 (m, 2H), 3.15 (m, 2H), 1.94-1.81 (m, 6H), 1.43-1.32 (app br s, 18H). 13C 
NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 169.0, 152.6, 137.9, 134.7, 126.5, 
119.8, 80.0, 63.0, 50.0, 35.2, 27.9. HRMS: Anal. calcd. for [M+H]+ 
C30H38N4O6S2: 615.2306; found 615.2278. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(([1,1'-biphenyl]-4,4'-
diylbis(azanediyl))bis(carbonyl))bis(piperidine-1-carboxylate) (6). A mixture 
of N-Boc-L-pipecolic acid (400 mg, 1.75 mmol), EDC (363 mg, 1.9 mmol), 
and benzidine (134 mg, 0.73 mmol) in CH2Cl2 (7 mL) was stirred at ambient 
temperature for 2 h. The resulting residue was partitioned between CH2Cl2 and 
H2O. The organic layer was washed with 1.0 N aq HCl solution and brine, dried 
over MgSO4, filtered, and concentrated in vacuo. A silica gel mesh was 
prepared from the residue and submitted to flash chromatography (silica gel: 
EtOAc/hexane as eluent) to provide 20 as a solid (186 mg, 42%). 1H NMR 
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(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.99 (s, 2H), 7.67-7.58 (dd, 8H), 4.70 (m, 
2H), 3.82 (d, 2H), 3.34 (m, 2H), 2.08 (app br s, 2H), 1.72-1.58 (m, 6H), 1.37 
(app br s, 22H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 170.8, 155.3, 
138.1, 134.5, 126.4, 119.7 78.9, 55.2, 53.9, 42.0, 28.0, 27.5, 24.2, 19.3. HRMS: 
Anal. calcd. for [M+H]+ C34H46N4O6: 607.3490; found 607.3491. 
 
(2R,2'R)-Di-tert-butyl 2,2'-(([1,1'-biphenyl]-4,4'-
diylbis(azanediyl))bis(carbonyl))bis(piperidine-1-carboxylate) (7). Yield 190 
mg (35%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.00 (s, 2H), 7.67-
7.58 (dd, 8H), 4.69 (m, 2H), 3.81 (d, 2H), 3.26 (m, 2H), 2.07 (app br s, 6H), 
1.64-1.58 (m, 6H), 1.37 (app br s, 22H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 
100 MHz): 170.8, 155.3, 138.1, 134.5, 126.4, 119.7, 78.9, 55.2, 53.9, 42.0, 28.0, 





Yield 86 mg (31%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.37 (app br 
s, 2H), 7.74-7.62 (m, 8H), 3.67 (m, 2H), 3.41 (m, 2H), 2.15 (m, 2H), 1.90 (m, 
6H), 1.51-1.26 (m, 24H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
173.0, 172.5, 153.0, 152.6, 138.4, 134.3, 126.1, 120.8, 120.6, 78.7, 78.6, 66.2, 
65.9, 47.5, 47.1, 28.2, 28.0, 22.6, 22.1, 21.1. HRMS: Anal. calcd. for [M+H]+ 




phenylethane-2,1-diyl))dicarbamate (11). Compound 17 (300 mg, 0.52 mmol) 
in CF3CO2H (2 mL) and CH2Cl2 (2 mL) was stirred at room temperature for 4 
h. The volatile component was removed in vacuo, EDCI (258 mg, 0.620 mmol) 
and 9 (260 mg, 1.24 mmol) were added in batches over 4 min to a solution of 
i-Pr2NEt (455 µL, 2.6 mmol) in CH2Cl2 (3 mL) and the reaction mixture was 
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stirred at room temperature for 75 min. The residue was partitioned between 
CH2Cl2 and H2O. The organic layer was washed with H2O and brine, dried over 
MgSO4, filtered, and concentrated in vacuo. A silica gel mesh was prepared 
from the residue and submitted to flash chromatography (silica gel: 
EtOAc/hexane as eluent) to provide 23 as a white solid (171 mg, 57%). 1H 
NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.14 (s, 2H), 7.68-7.60 (m, 9H), 
7.46-7.30 (m, 11H), 5.49 (d, 2H), 4.53 (m, 2H), 3.68 (m, 2H), 3.54 (s, 6H), 3.12 
(m, 2H), 2.00-2.13 (m, 2H), 1.89-1.82 (m, 6H). 13C NMR (DMSO-d6, δ = 39.52 
ppm, 100 MHz): 170.2, 168.1, 156.4, 138.2, 136.9, 134.4, 128.4, 128.4, 127.8, 
126.4, 119.4, 60.6, 56.6, 51.6, 46.9, 29.4, 24.7. HRMS: Anal. calcd. for [M+H]+ 




phenylethane-2,1-diyl))dicarbamate (12). Yield 48 mg (23%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.38 (s, 2H), 7.92 (d, 2H), 7.70-7.10 (m, 
18H), 5.46 (d, 2H), 4.94 (d, 2H), 4.25 (d, 2H) 3.89 (d, 2H), 3.54 (s, 6H), 3.06 
(m, 2H), 2.54 (m, 2H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 208.5, 
170.1, 169.4, 156.1, 137.8, 136.8, 134.7, 128.6, 128.2, 128.1, 126.5, 119.7, 57.4, 





phenylethane-2,1-diyl))dicarbamate (13). Yield 25 mg (14%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.89 (s, 2H), 7.93 (d, 2H), 7.73-7.59 (m, 
8H), 7.46-7.13 (m, 10H), 5.64 (d, 2H), 4.87 (m, 4H), 4.53 (d, 2H), 3.58 (s, 6H), 
3.36 (m, 2H), 3.19 (m, 2H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
168.3, 167.9, 156.4, 137.8, 136.3, 134.7, 128.7, 128.3, 128.1, 126.4, 119.8, 63.2, 
56.8, 51.8, 49.0, 33.1. HRMS: Anal. calcd. for [M+H]+ C40H40N6O8S2: 






phenylethane-2,1-diyl))dicarbamate (14). Compound 20 (73 mg, 0.12 mmol) 
in CF3CO2H (1 mL) and CH2Cl2 (1 mL) was stirred at room temperature for 5 
h. The volatile component was removed in vacuo, EDCI (60 mg, 0.31 mmol) 
and compound 9 (60 mg, 0.29 mmol) were added in batches over 4 min to a 
solution of i-Pr2NEt (105 µL, 0.60 mmol) in DMF (1 mL) and the reaction 
mixture was stirred at room temperature for 75 min. The residue was partitioned 
between CH2Cl2 and H2O. The organic soluble layer was washed with H2O and 
brine, dried over MgSO4, filtered, and concentrated in vacuo. A silica gel mesh 
was prepared from the residue and submitted to flash chromatography (silica 
gel: EtOAc/hexane as eluent) to provide 26 as a solid (12 mg, 13%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.99-9.84 (s, 2H), 7.85-7.30 (m, 20H), 
5.73-5.64 (m, 2H), 5.17/4.85 (m, 2H), 4.45/3.77 (m, 2H), 3.55 (app br s, 6H), 
3.18/2.83 (m, 2H), 2.15 (m, 2H), 1.76 (m, 2H), 1.63-1.24 (m, 8H). 13C NMR 
(DMSO-d6, δ = 39.52 ppm, 100 MHz): 170.0, 169.3, 168.5, 156.2, 138.0, 137.2, 
134.5, 128.6, 128.4, 128.2, 127.7, 126.5, 120.2, 119.7, 67.0, 55.5, 52.8, 51.6, 
43.2, 27.5, 25.1, 24.6, 19.7. HRMS: Anal. calcd. for [M+H]+ C44H48N6O8: 




phenylethane-2,1-diyl))dicarbamate (15). Yield 23 mg (15%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.98-9.84 (s, 2H), 7.84-7.28 (m, 20H), 
5.72-5.64 (m, 2H), 5.16/4.85 (m, 2H), 4.45/3.75 (m, 2H), 3.55 (app br s, 6H), 
3.17/2.83 (m, 2H), 2.15 (m, 2H), 1.76 (m, 2H), 1.63-1.23 (m, 8H). 13C NMR 
(DMSO-d6, δ = 39.52 ppm, 100 MHz): 170.0, 169.3, 168.5, 156.2, 138.0, 137.2, 
134.5, 128.6, 128.4, 128.2, 127.7, 126.5, 120.2, 119.7, 67.0, 55.5, 52.8, 51.6, 
43.2, 27.5, 25.1, 24.6, 19.7. HRMS: Anal. calcd. for [M+H]+ C44H48N6O8: 






1-phenylethane-2,1-diyl))dicarbamate (16). Yield 77 mg (41%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.03 (s, 1H), 8.89 (s, 1H), 7.77-7.57 (m, 
10H), 7.40-7.32 (m, 10H), 5.46 (m, 2H), 3.99 (m, 1H), 3.76 (m, 1H), 3.56 (s, 
3H), 3.54 (s, 3H), 3.48 (m, 1H), 3.21 (m, 1H), 2.18-2.08 (m, 2H), 1.91-1.80 (m, 
6H), 1.55 (s, 3H), 1.43 (s, 3H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
171.8, 171.7, 168.2, 167.7, 156.4, 156.2, 138.2, 138.0, 137.2, 136.5, 134.7, 
134.3, 128.7, 128.4, 128.22, 128.17, 127.70, 127.68, 126.09, 126.05, 120.9, 
120.3, 67.6, 67.5, 57.2, 57.0, 51.7, 51.6, 47.7, 47.5, 23.5, 23.1, 20.6, 20.5. 
HRMS: Anal. calcd. for [M+H]+ C44H48N6O8: 789.3606; found 789.3600. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((3,3'-dimethyl-[1,1'-biphenyl]-4,4'-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (17). A 
mixture of N-Boc-L-proline (9.47 g, 44.0 mmol), EDC (9.97 g, 52.0 mmol), and 
ortho-tolidine (4.25 g, 20.0 mmol) in CH2Cl2 (30 mL) was stirred at ambient 
temperature for 2 h. The resulting residue was partitioned between CH2Cl2 and 
H2O. The organic layer was washed with 1.0 N aq HCl solution and brine, dried 
over MgSO4, filtered, and concentrated in vacuo. Without any purification, 3 
was obtained as a solid (11.3 g, 93%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 
MHz): 9.35 (d, 2H), 7.51 (s, 2H), 7.48-7.42 (m, 4H), 4.34 (m, 2H), 3.45 (m, 
2H), 3.55 (m, 2H), 2.17 (s, 6H), 2.16 (m, 2H), 1.94-1.81 (m, 6H), 1.42-1.37 
(app br s, 18H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 171.4, 153.3, 
138.5, 135.4, 132.2, 128.3, 125.3, 124.0, 78.5, 59.9, 46.6, 31.4, 28.1, 23.3, 17.9. 
HRMS: Anal. calcd. for [M+H]+ C34H46N4O6: 607.3490; found 607.3480. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((2,2'-bis(trifluoromethyl)-[1,1'-biphenyl]-4,4'-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (18). Yield 
4.3 g (96%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.44 (d, 2H), 8.21 
(s, 1H), 8.14(s, 1H), 7.92-7.82 (dd, 2H), 7.33(m, 2H), 4.26 (m, 2H), 3.50-3.38 
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(m, 4H), 2.22 (m, 2H), 1.94-1.80 (m, 6H), 1.42 (s, 9H), 1.30 (s, 9H). 13C NMR 
(DMSO-d6, δ = 39.52 ppm, 100 MHz): 171.9, 171.6, 153.8, 153.2, 139.0, 132.0, 
131.0, 128.19, 128.15, 127.9, 124.9, 122.1, 121.2, 121.0, 116.34, 116.28, 116.2, 
116.1, 78.7, 78.6, 60.5, 60.1, 54.1, 46.6, 46.4, 31.0, 29.9, 27.8, 27.7, 24.0, 23.3. 
19F NMR (DMSO-d6, 377 MHz,): δ -57.37. HRMS: Anal. calcd. for [M+H]+ 
C34H40F6N4O6: 715.2925; found 715.2919. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((2,2'-dimethyl-[1,1'-biphenyl]-4,4'-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (19). Yield 
2.75 g (96%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.97 (s, 2H), 7.57-
7.41 (m, 4H), 6.97 (app br s, 2H), 4.26 (m, 2H), 3.42-3.35 (m, 4H), 2.21 (m, 
2H), 1.97 (s, 6H), 1.89-1.78 (m, 6H), 1.40-1.31 (app br s, 18H). 13C NMR 
(DMSO-d6, δ = 39.52 ppm, 100 MHz): 171.4, 171.0, 153.6, 153.2, 138.0, 138.0, 
135.69, 135.65, 129.52, 120.48, 120.47, 120.4, 120.3, 116.7, 116.5, 78.6, 78.4, 
60.3, 60.0, 46.7, 46.5, 31.3, 31.1, 30.2, 28.1, 28.0, 23.9, 23.3, 19.7. HRMS: 
Anal. calcd. for [M+H]+ C34H46N4O6: 607.3490; found 607.3489. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((2,2'-difluoro-[1,1'-biphenyl]-4,4'-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (20). Yield 
2.6 g (93%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.33 (s, 2H), 7.72-
7.68 (m, 2H), 7.46-7.36 (m, 4H), 4.28-4.19 (m, 2H), 3.45-3.32 (m, 4H), 2.22 
(m, 2H), 1.99-1.79 (m, 6H), 1.40-1.29 (app br s, 18H). 13C NMR (DMSO-d6, δ 
= 39.52 ppm, 100 MHz): 172.0, 171.6, 160.1, 157.7, 153.6, 153.1, 140.5, 140.4, 
131.58, 131.55, 117.0, 116.9, 115.1, 115.0, 106.2, 106.0, 78.74, 78.57, 60.4, 
60.1, 46.7, 46.6, 31.0, 30.2, 28.1, 28.0, 24.0, 23.4. 19F NMR (DMSO-d6, 377 




diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (21). Yield 
2.8 g (95%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.31 (app br s, 2H), 
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7.97-7.87 (m, 2H), 7.63-7.52 (m, 2H), 7.29-7.25 (m, 2H), 4.29-4.20 (m, 2H), 
3.47-3.41 (m, 2H), 3.38-3.32 (m, 2H), 2.25-2.19 (m, 2H), 1.92-1.82 (m, 6H), 
1.41-1.31 (app br s, 18H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
171.9, 171.5, 153.6, 153.1, 139.9, 132.5, 132.0, 131.6, 119.2, 117.6, 78.7, 78.5, 
60.4, 60.1, 46.7, 46.5, 31.3, 31.0, 30.1, 28.1, 28.0, 23.9, 23.3. HRMS: Anal. 
calcd. for [M+H]+ C32H40Cl2N4O6: 647.2398; found 647.2394. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((2,2'-dibromo-[1,1'-biphenyl]-4,4'-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (22). Yield 
990 mg (92%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.26 (s, 2H), 
8.12-8.01 (m, 2H), 7.66-7.55 (m, 2H), 7.23 (app br s, 2H), 4.26-4.20 (m, 2H), 
3.39-3.35 (m, 4H), 2.22 (m, 2H), 1.89-1.81 (m, 6H), 1.40-1.30 (app br s, 18H). 
13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 172.0, 171.6, 153.7, 153.1, 
139.9, 135.9, 131.4, 123.0, 122.3, 122.2, 118.2, 118.1, 78.8, 78.6, 60.5, 60.2, 
46.8, 46.6, 31.0, 30.2, 28.2, 28.0, 24.0, 23.4. HRMS: Anal. calcd. for [M+H]+ 




phenylethane-2,1-diyl))dicarbamate (23). Compound 3 (144 mg, 0.238 mmol) 
in CF3CO2H (1 mL) and CH2Cl2 (1 mL) was stirred at room temperature for 5 
h. The volatile component was removed in vacuo, EDCI (119 mg, 0.620 mmol), 
and 9 (100 mg, 0.572 mmol) were added in batches over 4 min to a solution of 
i-Pr2NEt (208 µL, 1.192 mmol) in CH2Cl2 (1 mL). The reaction mixture was 
stirred at room temperature for 75 min. The residue was divided between 
CH2Cl2 and H2O. The organic layer was washed with H2O and brine, dried over 
MgSO4, filtered, and concentrated in vacuo. A silica gel mesh was prepared 
from the residue and submitted to flash chromatography (silica gel: 
EtOAc/hexane as eluent) to provide 11 as a white solid (77 mg, 41%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.31 (s, 2H), 7.74 (d, 2H), 7.54-7.23 (m, 
16H), 5.52 (d, 2H), 4.52 (m, 2H), 3.85 (m, 2H), 3.52 (s, 6H), 3.18 (m, 2H), 2.28 
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(s, 6H), 2.00-1.82 (m, 8H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
170.1, 168.8, 156.1, 137.1, 136.5, 135.4, 132.2, 128.6, 128.2, 128.1, 128.0, 
125.2, 123.9, 60.6, 56.8, 51.6, 46.9, 29.1, 24.3, 17.9. HRMS: Anal. calcd. for 




diyl))bis(2-oxo-1-phenylethane-2,1-diyl))dicarbamate (24). Yield 145 mg 
(32%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.29 (s, 2H), 8.21 (d, 
2H), 7.83 (m, 2H), 7.75 (d, 2H), 7.43-7.05 (m, 12H), 5.51 (d, 2H), 4.41 (m, 2H), 
3.85 (app br s, 2H), 3.54 (s, 6H), 3.20 (app br d, 2H), 2.06-1.82 (m, 8H). 13C 
NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 171.26, 168.75, 156.42, 139.30, 
137.16, 132.79, 131.36, 128.89, 128.35, 128.25, 125.07, 122.88, 121.81, 116.37, 
61.05, 56.97, 51.87, 47.22, 29.45, 24.51. 19F NMR (DMSO-d6, 377 MHz,): δ -





phenylethane-2,1-diyl))dicarbamate (25). Yield 292 mg (73%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.84 (s, 2H), 7.73 (d, 2H), 7.59 (s, 2H), 
7.48-7.14 (m, 12H), 6.87 (d, 2H), 5.51 (d, 2H), 4.42 (m, 2H), 3.84 (m, 2H), 3.55 
(s, 6H), 3.20 (m, 2H), 1.98 (s, 6H), 1.97-1.78 (m, 8H). 13C NMR (DMSO-d6, δ 
= 39.52 ppm, 100 MHz): 170.2, 168.4, 156.1, 137.9, 137.1, 135.8, 135.8, 
129.58, 128.62, 128.1, 127.9, 120.5, 116.7, 60.7, 56.8, 51.7, 47.0, 29.4, 24.3, 




phenylethane-2,1-diyl))dicarbamate (26). Yield 134 mg (40%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.43 (s, 2H), 7.74-7.71 (m, 3H), 7.46-
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7.11 (m, 15H), 5.51 (d, 2H), 4.43 (m, 2H), 3.83 (m, 2H), 3.54 (s, 6H), 3.19 (m, 
2H), 2.05-1.77 (m, 8H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 170.8, 
168.4, 160.0, 158.0, 156.1, 140.5, 137.2, 131.6, 128.6, 128.5, 128.1, 127.9, 
127.6, 117.1, 115.1, 106.3, 106.1, 60.8, 56.7, 51.7, 47.0, 29.3, 24.3. 19F NMR 
(DMSO-d6, 377 MHz,): δ -73.45. HRMS: Anal. calcd. For [M+H]+ 




phenylethane-2,1-diyl))dicarbamate (27). Yield 146 mg (44%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.14 (s, 2H), 7.97-7.91 (m, 2H), 7.75 (d, 
2H), 7.65-7.55 (m, 2H), 7.43-7.12 (m, 12H), 5.51 (d, 2H), 4.39 (m, 2H), 3.84 
(m, 2H), 3.55 (s, 6H), 3.20 (m, 2H), 2.06-1.79 (m, 8H). 13C NMR (DMSO-d6, 
δ = 39.52 ppm, 100 MHz): 170.8, 168.5, 156.2, 139.9, 137.1, 132.6, 132.1, 
131.7, 128.6, 128.1, 127.9, 119.3, 117.7, 60.8, 56.73, 51.68, 47.0, 29.3, 24.3. 




phenylethane-2,1-diyl))dicarbamate (28). Yield 110 mg (42%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.13 (s, 2H), 8.32-8.12 (m,2H), 7.92-7.61 
(m, 4H), 7.41-7.13 (m, 12H), 5.51 (d, 2H), 4.39 (m, 2H), 3.84 (m, 2H), 3.55 (s, 
6H), 3.52 (m, 2H), 3.19 (m, 2H), 2.05-1.81 (m, 8H). 13C NMR (DMSO-d6, δ = 
39.52 ppm, 100 MHz): 170.7, 168.5, 156.2, 139.8, 137.1, 135.9, 131.3, 128.6, 
128.1, 127.9, 123.0, 122.3, 118.1, 60.8, 56.7, 51.7, 47.0, 29.3, 24.3. HRMS: 
Anal. calcd. for [M+H]+ C42H42Br2N6O8: 917.1504; found 917.1521. 
 
9,9-Difluoro-2,7-dinitro-9H-fluorene (30). 2,7-Nitro-9H-fluorene (100 mg, 
0.39 mmol) and N-fluorobenzenesulfonimide (NFSI) (369 mg, 1.17 mmol) 
were dissolved in DMF and cooled to -20°C. LiHMDS (1.0 M in THF, 1.17 mL, 
1.17 mmol) was added dropwise over 5 min. After an additional 2 h at 0°C, 
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TLC indicated the completion of the reaction, and the excess base was 
quenched by addition of MeOH. The suspension was filtered over Celite and 
concentrated in vacuo. A silica gel mesh was prepared from the residue and 
submitted to flash chromatography (silica gel: CH2Cl2/hexane as eluent) to 
provide 30 as a yellow solid (98 mg, 86%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 
400 MHz): 8.63 (d, 2H), 8.53 (d, 1H), 8.56 (d, 1H), 8.36 (s, 1H), 8.34 (s, 1H). 
13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 149.1, 142.5, 138.5, 129.2, 
144.3, 120.8, 119.6. 19F NMR (DMSO-d6, 377 MHz,): δ -110.3. 
 
9,9-Dimethyl-2,7-dinitro-9H-fluorene (31). A mixture of 2,7-nitro-9H-
fluorene (100 mg, 0.39 mmol) and NaOt-Bu (75 mg, 0.78 mmol) were 
dissolved in DMF at ice bath under N2. Then, CH3I (49 µL, 0.78 mmol) was 
slowly added to the mixture, and stirred for 2 h. The solution was poured into 
water and a precipitate was formed. The product was filtered, washed with 
water, and air-dried. Without any purification, 31 (89 mg, 80%) was obtained 
as a yellow solid. 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 8.59 (d, 2H), 
8.33 (m, 4H), 1.60 (s, 6H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 
156.2, 148.1, 142.7, 123.6, 122.9, 118.7, 47.9, 25.6. 
 
9,9-Difluoro-9H-fluorene-2,7-diamine (32). A magnetic stirrer bar, Fe3O4 
(purchased from Aldrich, 4 mg, 0.015 mmol), and DMF (0.5 mL) were added 
to an oven-dried Schlenk tube, and the mixture was sonicated in an ultrasound 
bath for 1 min under argon. Compound 31 (22 mg, 0.075 mmol) and hydrazine 
monohydrate (29 µL, 0.60 mmol) were then added to the mixture. The reaction 
mixture was stirred at 80°C under an argon atmosphere until the reaction was 
completed. After magnetic separation of the catalyst, the organic layer was 
concentrated in vacuo. The residue was partitioned between CH2Cl2 and H2O. 
The organic layer was washed with brine, dried over MgSO4, filtered, and 
concentrated in vacuo. Without any purification, 32 (17 mg, 98%) was obtained 
as a yellow solid. 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 7.19 (s, 1H), 
7.17 (s, 1H), 6.8 (d, 2H), 6.61 (d, 1H), 6.59(d, 1H), 5.3 (s, 4H). 13C NMR 
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(DMSO-d6, δ = 39.52 ppm, 100 MHz): 148.0, 137.3, 137.1, 127.7, 123.7, 119.8, 
116.45, 109.1. 19F NMR (DMSO-d6, 377 MHz,): δ -106.7. HRMS: Anal. calcd. 
for [M+H]+ C13H10F2N2: 233.0885; found 233.0885. 
 
9,9-Dimethyl-9H-fluorene-2,7-diamine (33). Yield of 69 mg (98%) was 
obtained as a yellow solid. 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 7.21 
(s, 1H), 7.19 (s, 1H), 6.6 (d, 2H), 6.47 (d, 1H), 6.45(d, 1H), 4.9 (s, 4H), 1.3 (s, 
6H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 153.5, 146.7, 128.4, 
118.6, 112.6, 108.5, 45.6, 27.7. HRMS: Anal. calcd. for [M+H]+ C15H16N2: 
225.1386; found 225.1383. 
 
2,7-Diamino-9H-fluoren-9-one (35). A mixture of 9H-fluorene-2,7-diamine 
(294 mg, 1.5 mmol) and Cs2CO3 (1.5 g, 4.5 mmol) in DMSO (7 mL) was stirred 
under an atmosphere of air. When TLC showed that no starting material 
remained, the solution was poured into water and a precipitate was formed. The 
product was filtered, washed with water, and air-dried. Without any purification, 
35 (239 mg, 76%) was obtained as a solid. 1H NMR (DMSO-d6, δ = 2.5 ppm, 
400 MHz): 7.10 (s, 1H), 7.08 (s, 1H), 6.70 (d, 2H), 6.57 (d, 1H), 6.57 (d, 1H) 
5.30 (s, 4H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 194.9, 148.2, 
134.6, 133.3, 119.9, 118.6, 109.7. HRMS: Anal. calcd. for [M+H]+ C13H10N2O: 
211.0866; found 211.0867. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((9H-fluorene-2,7-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (36). A 
mixture of N-Boc-L-proline (323 mg, 1.5 mmol), EDCI (312 mg, 1.63 mmol), 
and 2,7-diaminofluorene (123 mg, 0.63 mmol) in CH2Cl2 (2 mL) was stirred at 
ambient temperature for 2 h. The resulting residue was partitioned between 
CH2Cl2 and H2O. The organic layer was washed with 1.0 N aq HCl solution 
and brine, dried over MgSO4, filtered, and concentrated in vacuo. Without any 
purification, 36 was obtained as a solid (359 mg, 97%). 1H NMR (DMSO-d6, δ 
= 2.5 ppm, 400 MHz): 10.0 (d, 2H), 7.69 (d, 2H), 7.72 (d, 2H), 7.57-7.51 (m, 
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2H), 4.31-4.21 (m, 2H), 3.88 (s, 2H), 3.45-3.37 (m, 4H), 2.23 (m, 2H), 1.94-
1.80 (m, 6H), 1.41 (app br s, 9H), 1.29 (app br s, 9H). 13C NMR (DMSO-d6, δ 
= 39.52 ppm, 100 MHz): 171.4, 153.2, 143.5, 137.6, 136.3, 119.5, 118.0, 116.1, 
78.6, 78.5, 60.4, 46.6, 31.1, 28.2, 28.0, 24.0, 23.4. HRMS: Anal. calcd. for 
[M+H]+ C33H42N4O6: 591.3177; found 591.3168. 
 
(2S,2'S)-di-tert-butyl 2,2'-(((9-oxo-9H-fluorene-2,7-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (37). Yield 
131 mg (91%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.24 (s, 2H), 
7.91 (m, 2H), 7.91 (m, 2H), 7.62 (m, 2H), 4.26-4.16 (m, 2H), 3.46-3.40 (m, 2H), 
3.37-3.31 (m, 2H), 2.24-2.16 (m, 2H), 1.94-1.76 (m, 6H), 1.40 (app br s, 9H), 
1.27 (app br s, 9H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 192.9, 
171.9, 171.4, 153.6, 153.1, 139.6, 138.8, 134.2, 125.0, 121.1, 115.0, 78.8, 78.6, 
60.5, 60.1, 46.6, 46.1, 31.0, 30.2, 28.2, 28.0, 24.0, 23.4. HRMS: Anal. calcd. 
for [M+H]+ C33H40N4O7: 605.2970; found 605.2980. 
 
(2S,2'S)-di-tert-butyl 2,2'-(((9,9-dimethyl-9H-fluorene-2,7-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (38). Yield 
201 mg (97%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.10 (app br s, 
2H), 7.84 (s, 1H), 7.79 (s, 1H), 7.66 (d, 2H), 7.51 (t, 2H), 4.31-4.28 (m, 1H), 
4.24-4.21 (m, 1H), 3.44-3.40 (m, 2H), 3.37-3.31 (m, 2H), 2.21-2.16 (m, 2H), 
1.95-1.80 (m, 6H), 1.40 (app br s, 9H), 1.34 (s, 6H), 1.28 (app br s, 9H). 13C 
NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 174.3, 173.9, 171.4, 171.0, 153.6, 
153.2, 138.1, 138.0, 133.7, 133.6, 119.7, 118.4, 118.2, 113.8, 113.6, 78.6, 78.5, 
60.4, 60.0, 46.6, 46.1, 42.2, 42.1, 31.0, 30.3, 28.2, 28.1, 27.9, 27.1, 24.0, 23.4. 
HRMS: Anal. calcd. for [M+H]+ C35H42N4O6: 619.3490; found 619.3496. 
 
(2S,2'S)-Di-tert-butyl 2,2'-(((9,9-difluoro-9H-fluorene-2,7-
diyl)bis(azanediyl))bis(carbonyl))bis(pyrrolidine-1-carboxylate) (39). Yield 
28 mg (95%). 1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.29 (app br s, 
2H), 8.06 (s, 1H), 8.02 (s, 1H), 7.69-7.66 (m, 4H), 4.30-4.25 (m, 1H), 4.21-4.18 
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(m, 1H), 3.45-3.41 (m, 2H), 3.37-3.34 (m, 2H), 2.23-2.16 (m, 2H), 1.92-1.80 
(m, 6H), 1.40 (app br s, 9H), 1.27 (app br s, 9H). 13C NMR (DMSO-d6, δ = 
39.52 ppm, 100 MHz): 174.3, 173.9, 171.9, 171.5, 153.6, 153.1, 139.4, 133.56, 
133.49, 122.8, 122.7, 121.2, 114.5, 114.4, 78.8, 78.6, 60.5, 59.3, 58.6, 46.6, 
46.2, 46.1, 31.0, 30.3, 28.2, 28.0, 27.9, 27.7, 24.0, 23.4. 19F NMR (DMSO-d6, 
377 MHz,): δ -108.9, -109.0. HRMS: Anal. calcd. for [M+H]+ C33H40F2N4O6: 




phenylethane-2,1-diyl))dicarbamate (40). A mixture of biphenyl 36 (300 mg, 
0.51 mmol) in CF3CO2H (2 mL) and CH2Cl2 (2 mL) was stirred at room 
temperature for 5 h. The volatile component was removed in vacuo. EDCI (253 
mg, 1.3 mmol) and 9 (255 mg, 1.3 mmol) were added in batches over 4 min to 
a solution of i-Pr2NEt (441 µL, 2.5 mmol) in CH2Cl2 (2 mL), and the reaction 
mixture was stirred at room temperature for 75 min. The residue was partitioned 
between CH2Cl2 and H2O. The organic layer was washed with H2O and brine, 
dried over MgSO4, filtered, and concentrated in vacuo. A silica gel mesh was 
prepared from the residue and submitted to flash chromatography (silica gel: 
EtOAc/hexane as eluent) to provide 40 as a white solid (198 mg, 50%). 1H 
NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.92 (s, 2H), 7.91 (s, 2H), 7.75-7.69 
(m, 4H), 7.56 (d, 2H), 7.44-7.13 (m, 10H), 5.52 (d, 2H), 4.43 (m, 2H), 3.88-
3.83 (m, 2H), 3.55 (s, 6H), 3.21 (m, 2H), 2.04-1.78 (m, 8H). 13C NMR (DMSO-
d6, δ = 39.52 ppm, 100 MHz): 170.2, 168.5, 156.2, 143.6, 137.5, 137.2, 136.4, 
128.7, 128.1, 127.9, 119.6, 118.1, 116.2, 60.8, 56.8, 51.7, 47.0, 36.7, 29.4, 24.3. 




phenylethane-2,1-diyl))dicarbamate (41). Yield 12 mg (66%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.10 (s, 2H), 7.91 (s, 2H), 7.76 (t, 4H), 
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7.64 (d, 2H), 7.43-7.10 (m, 10H), 5.51 (d, 2H), 4.39 (m, 2H), 3.85 (m, 2H), 3.55 
(s, 6H), 3.20 (m, 2H), 2.05-1.79 (m, 8H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 
100 MHz): 192.8, 170.6, 168.5, 156.2, 139.5, 138.8, 137.1, 134.2, 128.6, 128.1, 
127.9, 125.0, 121.1, 115.0, 60.8, 56.7, 51.7, 47.0, 29.3, 24.3. HRMS: Anal. 




phenylethane-2,1-diyl))dicarbamate (42). Yield 135 mg (53%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 9.96 (s, 2H), 7.86 (s, 2H), 7.74 (d, 2H), 
7.69 (d, 2H), 7.51 (dd, 2H), 7.43-7.10 (m, 10H), 5.52 (d, 2H), 4.43 (m, 2H), 
3.83 (m, 2H), 3.55 (s, 6H), 3.20 (m, 2H), 2.05-1.78 (m, 8H), 1.41 (s, 6H). 13C 
NMR (DMSO-d6, δ = 39.52 ppm, 100 MHz): 170.1, 168.3, 156.1, 153.7, 138.0, 
137.2, 133.7, 128.6, 128.1, 127.8, 119.8, 118.3, 113.7, 60.7, 56.7, 51.6, 47.0, 





phenylethane-2,1-diyl))dicarbamate (43). Yield 18 mg (52%). 1H NMR 
(DMSO-d6, δ = 2.5 ppm, 400 MHz): 10.14 (s, 2H), 8.05 (s, 2H), 7.77 (d, 2H), 
7.71 (s, 4H), 7.43-7.10 (m, 10H), 5.51 (d, 2H), 4.39 (m, 2H), 3.85 (m, 2H), 3.55 
(s, 6H), 3.21 (m, 2H), 2.06-1.79 (m, 8H). 13C NMR (DMSO-d6, δ = 39.52 ppm, 
100 MHz): 170.6, 168.5, 156.2, 139.3, 137.3, 137.0, 128.6, 128.4, 128.1, 127.9, 
127.6, 122.8, 121.2, 114.5, 60.8, 56.7, 51.6, 47.0, 29.3, 24.3. HRMS: Anal. 








- Cell line and cell culture 
Huh 7.5.1 cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM; 
Gibco) supplemented with antibiotics (100 U/mL penicillin, 10 µg/mL 
streptomycin) and 10% heat-inactivated fetal bovine serum (ΔFBS; Thermo) at 
37°C in a humidified 6.0% CO2 incubator. 
 
- Virus production 
In vitro transcription and RNA electroporation were performed as described 
in the previous report.101 In vitro transcribed RNA of JFH5a-Rluc-ad34, which 
is a derivative of JFH1 with adaptive mutations in the E2 and p7 regions,28 was 
transfected into Huh7.5.1 cells by electroporation. JFH5a-Rluc-ad34 virus 
contains a reporter Renilla luciferase (Rluc) for convenient assay of virus 
proliferation.28 Cell culture media containing HCV were collected 3~5 days 
after electroporation and then filtered through a 0.45 µM pore size filter. 
 
- Antiviral activity test with infectious HCV particles  
Huh 7.5.1 cells were inoculated with a JFH5a-Rluc-ad34 virus stock and 
cultivated for 3 h. At 3 h after the virus inoculation, HCV-infected Huh7.5.1 
cells were cultivated with media containing serially diluted compounds. At 3 
days after chemical treatment (All of the compounds purity were 92% at least), 
the cells were harvested and luciferase activities in the cells were measured 
using a Renilla luciferase assay system (Promega) according to the 
manufacturer’s direction. Finally the luciferase activities were normalized to 
those obtained from mock-treated cells. 
 
2. Measurement of anti-HCV activities of compounds using HCV replicon  
 
- Cell line and cell culture 
Huh 7.5.1 cells containing a bicistronic HCV replicon NK/R2AZ (genotype 
1b) were used to test the anti-HCV activities of the compounds (Figure I-6). 
The first and second open reading frames (ORFs) of the replicon contain the 
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Renilla luciferase gene fused with the neomycin phosphotransferase gene and 
the HCV nonstructural genes NS3-5, respectively. The replicon-containing 
cells were cultivated under the same conditions as described above with an 
additional antibiotic G418 (0.5 mg/ml, Calbiochem). 
 
 
Figure I-6. The structure of replicon NKR2AN 
 
- Antiviral activity assay test with HCV replicon 
Huh 7.5.1 cells containing HCV replicon (NK/R2AN) were plated on a 12-
well plate (5 x 104 cells per well). At 16 h after cultivation, NK/R2AN-
containing cells were incubated with media containing serially diluted 
compounds for 3 days. After the chemical treatment, the cells were harvested 
and luciferase activities were measured. Luciferase activities were measured 
using the Renilla luciferase assay system (Promega) according to the 
manufacturer’s direction, and then normalized to those obtained from mock-
treated cells. 
 
3. Observation of the effects of co-treatment of two compounds 
Huh 7.5.1 cells containing HCV replicon (NK/R2AN) were plated on a 12-
well plate (5 x 104 cells per well). At 16 h after cultivation, NK/R2AN cells 
were treated with serially diluted compounds in the presence of 123 nM of 
sofosbuvir (EC30). At 3 days after treatment, luciferase activities were measured 
using the Renilla luciferase assay system (Promega) according to the 
manufacturer’s direction. 
 




We selected HCV mutants showing resistance against BMK-20113 by 
continuous cultivation of Huh 7.5.1 cells containing HCV replicon NK/R2AN 
in the presence of BMK-20113. We found that the majority of mutants had 
mutations at the N-terminal region of NS5A protein (L31V and/or Y93H in 
NS5A) similarly to the daclatasvir resistant mutants described previously.96,102 
We used NK/R2AN derivatives containing single mutations (L31V or Y93H in 
NS5A) to investigate the drug resistance of lead compounds. Briefly, Huh 7.5.1 
cells were electroporated with RNAs containing resistant mutations and 
cultivated on 12-well plates. At 4 h after transfection, media were replaced with 
DMEM containing serially diluted compounds and further cultivated. At 3 days 
after compound treatment, the cells were harvested and luciferase activities 
were measured. Luciferase activities were normalized to those obtained from 
mock-treated cells. 
 
5. hERG ligand binding assay82 
The hERG ligand binding assay was performed by using the hERG 
Fluorescence Polarization Assay Kit (Cat No. PV5365), containing predictorTM 
hERG tracer red, predictorTM hERG membrane, and predictorTM hERG FP 
assay buffer. Test compounds (10 µM) and positive control (Astemizole) were 
added to the 384-well plate (5 µL each; low-volume polystyrene plate, corning 
#3677). Then, 10 µL of membrane and 5 µL of tracer were added to each plate 
by using a multi-pipette (Multi 16 channel pipette type 5–50 µL, Thermo). The 
plate was then covered with aluminum foil and was kept for 2–3 h at room 
temperature. Lastly, the fluorescence polarization of the hERG red tracer was 
measured using a microplate reader (molecular devices, SpectraMax M5e, 
excitation (540 nm) emission (585 nm) filters). 
 
6. Plasma stability measurement 
Rat plasma (297 µL) was pre-incubated for 5 min at 37°C in a water bath. The 
plasma and 100 µM test compounds (3 µL) were mixed using a vortex, and 
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incubated for 37°C in a water bath. Then the mixture was sampled multiple 
times (0, 15, 30, 60, and 120 min). A mixture of crude sample (50 µL) and 
acetonitrile (100 µL) was then treated by centrifugation at 10,000 rpm for 10 
min at 25°C. Finally, supernatant was isolated and analyzed using a LC-MS/MS. 
 
7. Method to determine stability in rat and human liver microsomes84 
The metabolic stability of the compounds was evaluated in pooled rat (BD 
Gentest® Cat No. 452501) or human livers (BD GentestCat. 452161) 
microsomal fractions with β-NADPH over 30 m using 1 µM of compounds. 
The compounds in the supernatants were analyzed by LC-MS/MS. 
 
8. Method of CYP450 Inhibition 
The interaction of human cytochrome CYP450 with compounds was studied 
on a cytochrome panel consisting of CYP1A2, CYP2C9, CYP2C19, CYP2D6, 
and CYP3A4 (P450-glo, promega kit) according to the manufacturer’s 
protocols. The inhibition effects were measured at 100, 50, 10, 5, 1, 0.1, and 
0.01 µM of compounds using a luminometer (GENios, TECAN). 
 
9. PK study 
Pharmacokinetic studies were conducted in a parallel format with 2 male and 
1 female Sprague-Dawley rats (supplied by Sippr-BK Lab Animal Ltd., 
Shanghai, China) for compounds per each dose routes. For Intravenous (IV) 
dose, administrated via tail vein as a bolus injection by nominal 5 mg/kg as a 
solution (5% DMSO, 10% solutol, 85% (2-hydroxypropyl)-β-cyclodextrin 
(HPBCD)). Blood samples were collected into polypropylene tubes containing 
K2-EDTA as anticoagulant at different time points and stored on wet ice. The 
samples were centrifuged at 8,000 rpm for 6 min and the plasma samples were 
determined with LC/MS/MS. Non-compartmental pharmacokinetic analysis 
was performed with drug and statistics (DAS) 2.1.1 pharmacokinetic program. 
 
10. Ames test99 
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The Ames test of compound was carried out with the Maron’s method133 using 
histidine-dependent strains of Salmonella typhimurium (TA98, and TA100). 
Histidine requiring bacteria of each strain was treated with inhibitor compound 
43 at 200 µg/plate and with positive (2-nitrofluorene, sodium azide, and 
benzo[a]pyrene) and negative controls. The number of colonies was counted 
three times for each medium to provide acceptable data for statistical analysis.   
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Synthesis of conjugated polymers 













Conjugated polymers (CPs) have received much attention as the key materials 
for organic electronic devices, such as organic photovoltaics (OPVs),1,2 organic 
light emitting diodes (OLEDs),3 and organic thin film transistors (OTFTs)4 
owing to their intriguing optoelectronic property, solution processability, 
flexibility, and low-cost manufacturing potential. Therefore, much interest has 
been concentrated on developing efficient synthetic methods for well-defined 
CPs. The syntheses of CPs have been mostly accomplished using two types of 
transition metal-catalyzed polymerization reactions. The first method involves 
a chain-growth polymerization approach, such as nickel (Ni)-catalyzed 
Kumada catalyst-transfer polycondensation (KCTP),5,6 palladium (Pd)-
catalyzed catalyst-transfer Suzuki-Miyaura coupling polymerization,7 as well 
as ruthenium (Ru)-catalyzed cyclopolymerization8-10 and ring opening 
metathesis polymerization (ROMP).11,12 The second method, a more commonly 
used one, involves a step-growth polymerization approach based on Pd-
catalyzed Heck, Suzuki, and Stille reactions as well as Ni-catalyzed Yamamoto 
coupling reaction.2,13,14 Although homogeneous catalysis using transition 
metals has achieved great success in the synthesis of CPs, it suffers from 
residual contamination from the use of metal catalysts and ligands. This is 
because it is difficult to remove those contaminants by simple physical methods 
such as filtration and centrifugation. The residual contaminants reduce the 
electrical properties of CPs; this affects the evaluation of intrinsic properties of 
the CPs and makes the comparison of the properties of various CPs difficult.15-
18 Therefore, easy and convenient separation methods to reduce the residual 
contaminant level are highly desirable. Moreover, from the economic and 
environmental perspectives, the recycling of the catalysts for polymerization by 
employing heterogeneous catalysts is most desired. In 2012, the Chen group 
successfully achieved the synthesis of the CPs using heterogeneous Pd on 
carbon by (Pd/C)-catalyzed Heck, Suzuki, and Stille coupling reactions.19 
However, the catalytic activity of the recovered heterogeneous catalyst 
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diminished after a single reaction, and attempts to recycle the catalyst were not 
successful.19 
Recently, because of greater surface-to-volume ratio and well-defined three-
dimensional structures, nanocrystals have attracted much attention as 
heterogeneous catalysts; they exhibit significantly increased activity and 
sometimes even selectivity over the conventional heterogeneous catalysts.20-22 
Because the metal nanoparticle catalysts are well dispersed in solution, they 
almost act as semi-homogeneous catalysts.20 In particular, Pd-Fe3O4 HNCs 
have exhibited consistent high catalytic activities in many organic reactions 
owing to their relatively uniform size (approximately 8 and 65 nm for Pd and 
Fe3O4, respectively). Furthermore, because of their soft ferrimagnetic property, 
the magnetic HNCs can be easily recovered using an external magnet and 
recycled without resorting to cumbersome filtration or centrifugation.23 
Recently, we synthesized gram quantities of Pd-Fe3O4 HNCs and successfully 
applied the magnetic nanocrystals, in the absence of extra ligands, to various 
organic reactions such as Suzuki,23 Heck,24 and Sonogashira coupling 
reactions,24 as well as direct C-H arylation25 and Wacker oxidation reaction.26 
Herein, we report the first application of nanocrystal catalysis toward the 
synthesis of CPs via Suzuki polymerization using Pd-Fe3O4 HNCs. In the 
synthesis of CPs, we particularly focused on the recycling of the catalyst; this 
is one of the most important goals toward sustainable or green chemistry.27,28 
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2. Result and Discussion 
 
To test the feasibility of the polycondensation via nanocatalysis, 1,4-
diiodobenzene, 9,9-di(2′-ethylhexyl)fluorene-2,7-diboronic acid, and 2 mol% 
Pd-Fe3O4 catalyst were subjected to various polymerization conditions. We 
observed that several factors affected the efficiency of the polymerization. 
Because Pd-catalyzed Suzuki coupling reactions are known to be dependent 
upon a base,29,30 several bases such as potassium acetate (KOAc), dipotassium 
hydrogen phosphate (K2HPO4), potassium phosphate (K3PO4), and sodium 
carbonate (Na2CO3) were investigated first (Table II-1, entries 1–4). The best 
result was obtained when 5 equiv of K3PO4 was used to afford the conjugated 
polymer in a good yield after the precipitation (Table II-1, entry 4). When less 
than 5 equiv of K3PO4 was used, both the yields and number average molecular 
weights (Mn) of the CPs decreased dramatically (Table II-1, entry 5). We then 
examined the solvents for the polymerization, considering that the Pd-Fe3O4 
catalyst is well dispersed in polar solvents. While choosing solvents, the 
solubility of the CPs was also taken into consideration. First, N,N’-
dimethylformamide (DMF) was investigated because it is well known to 
stabilize Pd catalysts;14,31 however, a low molecular weight polymer was 
obtained in low yield (Table II-1, entry 11). When ethereal solvents such as 1,4-
dioxane and tetrahydrofuran (THF) were used, good conversions were obtained 
(Table II-1, entries 10 and 4, respectively). Because the solubility of the 
polymer was better in THF than in 1,4-dioxane, slightly higher yields and Mn 
of the polymer in THF were observed than that in 1,4-dioxane. When a 3:1 v/v 
mixture of THF and water was used, the dispersion of the catalyst was poor, 
resulting in an aggregation of the catalyst in the reaction vessel, i.e., the Schlenk 
tube; this led to a low Mn of the resulting polymer (Table II-1, entry 16). 
Therefore, THF was selected as the reaction solvent. With the optimum base (5 
equiv of K3PO4) and solvent (THF) in hand, we examined the reaction 
temperature by comparing the reactions at 70 and 110 °C. At both the 
temperatures, the reactions proceeded well (Table II-1, entries 4 and 6). Next, 
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the catalyst loading was varied from 0.5 to 5 mol%; 2 mol% catalyst was found 
optimal. This is because a higher catalyst loading did not increase the molecular 
weight and only a small amount of the polymer was produced when the catalyst 
loading was reduced to 0.5 mol% (Table II-1, entries 7 and 8). Thus, the 
optimized reaction conditions are as follows: 0.15 M substrate in the presence 
of 2 mol% Pd-Fe3O4 and 5 equiv K3PO4 in THF. 
 
Table II-1. Condition optimization for Suzuki polymerization 






Entry Solvent Base Time (hr) 
temp 
(°C) Mn
a Mwa PDIa Yield 
1 THF Na2CO3 (5 eq) 72 110 trace amount 
2 THF K2HPO4  (5 eq) 72 110 trace amount 
3 THF KOAc (5 eq) 72 110 trace amount 
4 THF (0.15M) K3PO4 (5 eq) 72 110 15.2k 41.4k 2.72 96% 
5 THF K3PO4 (3 eq) 72 110 trace amount 
6 THF (0.15M) K3PO4 (5 eq) 72 70 15.6k 56.7k 3.63 95% 
7b,c THF (0.15M) K3PO4 (5 eq) 72 110 12.7k 53.3k 4.20 94% 
8d THF (0.15M) K3PO4 (5 eq) 72 110 n.d. 13% 
9e THF (0.15M) K3PO4 (5 eq) 72 70 no precipitates 
10 1,4-dioxane K3PO4 (5 eq) 72 105 13.0k 32.8k 2.52 84% 
11 DMF K3PO4 (5 eq) 72 160 4.3k 8.9k 2.07 31% 
12 Toluene K3PO4 (5 eq) 72 100 no precipitates 
13f toluene/H2O (v/v=3/1) K3PO4 (5 eq) 72 100 4.8k 11.2k 2.33 49% 
14f toluene/H2O (v/v=1/1) K2CO3 (10 eq) 72 100 n.d. 24% 
15f toluene/H2O (v/v=1/1) 
Na2CO3  
(10 eq) 72 100 n.d. 29% 
16 THF/H2O (v/v=3/1) K3PO4 (5 eq) 72 100 7.0k 13.3k 1.90 87% 
17b THF/H2O (v/v=3/1) K2CO3 (5 eq) 48 100 8.1k 27.2k 3.36 76% 
18b THF/H2O (v/v=3/1) Cs2CO3 (5 eq) 48 100 2.7k 7.1k 2.63 73% 
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19 THF/MeOH (v/v=4/1) Cs2CO3 (5 eq) 72 100 n.d. 36% 
20b THF/DMA (v/v=4/1) K3PO4 (5 eq) 72 110 3.4k 15.4k 4.53 86% 










Cs2CO3 (5 eq) 48 90 2.2k 6.1k 2.77 78% 
24b DMA/H2O (v/v=4/1) K2CO3 (5 eq) 72 100 1.9k 7.5k 3.95 83% 
25b DMA/H2O (v/v=4/1) K3PO4 (5 eq) 72 100 0.8k 2.1k 2.63 46% 
a Determined by THF size exclusion chromatography (SEC) calibrated using 
polystyrene (PS) standards. Mn is given in g/mol. b Determined by CHCl3 SEC 
calibrated using PS standards. Mn is given in g/mol. c 5 mol% of Pd-Fe3O4 was used. d 
0.5 mol% of Pd-Fe3O4 was used. e Fe3O4 was used rather than Pd-Fe3O4. f A drop of 
Aliquat 336 was added. 
 
With the optimized reaction conditions in hand, the substrate scope of the 
Suzuki polymerization using the Pd-Fe3O4 HNC catalyst was investigated. 
Depending on the length and branching of the side chains, the properties of CPs 
such as the electronic performance could vary.32,33 With this consideration, we 
carried out the polymerization of 1,4-diiodobenzene with the fluorenes 
containing linear alkyl chains, such as 9,9-didodecylfluorene-2,7-diboronic 
acid (Table II-2, entry 1) and 9,9-dioctylfluorene-2,7-diboronic acid bis(1,3-
propanediol) ester (Table II-2, entry 2). Regardless of the side-chain structures, 
moderate to high molecular weight polymers were obtained in high yields 
(Table II-1, entry 6; Table II-2, entries 1 and 2). The choice between a boronic 
acid and boronic ester may affect the efficiency of Suzuki 
polycondensation.34,35 In this study, the polymerizations between the diboronic 
ester and several diiodoarenes were also successful (Table II-2, entries 2-4). 
However, the reaction of 1,4-diiodo-2,3,5,6-tetramethylbenzene, 2,7-diiodo-
9,9-dioctyl-9H-fluorene, or 2,7-diiodo-9,9-didodecyl-9H-fluorene with the 
boronic ester did not proceed smoothly to afford the desired polymers (Table 
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II-2, entries 8–10). It appears that the oxidative addition of the diiodo 
monomers containing bulky side chains is challenging, resulting in lower 
conversions. Next we attempted couplings of 1,4-dibromobenezene or 
dibromothiophene derivatives as monomers with a boronic acid or ester, but 
only a trace to small amount of desired polymer was obtained (Table II-2, 
entries 11–13). The low conversion of dibromoarenes is similar to the results 
observed with monomer reactions using bromoarenes with the same Pd-Fe3O4 
nanoparticles.23 Therefore, the diiodo compounds, substituted with either short 
or no side chains such as meta-diiodobenzene and monomers of thiophene 
derivatives, were used to ensure successful Suzuki polymerization (Table II-2, 
entries 4–7). The most notable example in this regard is reported in entry 7 of 
Table II-2, where the bithiophene unit was successfully incorporated into the 
polymer to give F12T2, the didodecyl analog of the well-known polymer, 
poly(9,9-dioctylfluorene-alt-bithiophene) (F8T2), for OTFT applications.36 All 






Table II-2. Synthesis of conjugated polymers using Pd-Fe3O4 catalyst 
Entry Monomers Mna PDIa Yield 
1 (HO)2B B(OH)2
n Dodecyl n Dodecyl
+I I
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5 (HO)2B B(OH)2




14.9 k 2.47 >99% 
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a Determined by THF SEC calibrated using PS standards. Mn is given in 





Figure II-1. Recovery of Pd-Fe3O4 HNC using external magnet after 
polymerization (a) without magnet (b) with magnet. 
 
The ferrimagnetic characteristics of Pd-Fe3O4 HNCs allowed for easy 
recycling of the catalyst using an external magnet (Figure II-1). Because of the 
relationship between the Mn and conversion in step-growth polymerization, the 
resulting polymers would be obtained with significantly lower Mn and lower 
yield if the catalyst activity decreases during the recycling. Therefore, it is of 
utmost interest to maintain the performance of the heterogeneous catalyst 
system in repetitive polymerization. When the recycling experiments of the Pd-
Fe3O4 HNC catalyst for the polymerization of 1,4-diiodobenzene and 9,9-
didodecylfluorene-2,7-diboronic acid were carried out, the corresponding CPs 
were obtained in high yield and with a similar level of Mn (≥11.3 kg/mol) up to 
at least sixth recycling (Table II-3). In the case of the polymerization of 1,4-
diiodobenzene and 9,9-di(2′-ethylhexyl)fluorene-2,7-diboronic acid, the 
recycling experiments were carried out at both 70 and 110 °C. At 70 °C, the 
catalyst in the polymerization was reused for at least 11 times, (or 10 times at 
110 °C, Table II-4 (a) and (b), respectively). It was crucial to sonicate the 
reaction flask containing the recycled catalyst and fresh batch of monomers 
before the reaction, because the Pd-Fe3O4 HNC catalyst should be well-
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dispersed in THF for successful polymerization. Without the sonication 
treatment, the catalytic activity dropped precipitously, presumably because of 
the aggregation of the Pd-Fe3O4 HNC catalyst during the recycling process 
(Table II-4 (c)).36 The transmission electron microscopy (TEM) images of the 
fresh Pd-Fe3O4 HNC catalyst and that after the fifth recycling at 70 °C showed 
the same morphology (Figure II-2, inset (b) shows the image after 11 times 
recycling). Moreover, even after 11 times recycling, the recovered weight of 
the Pd-Fe3O4 HNC catalyst was 89% of the original amount. The Pd content of 
the catalyst, determined by ICP-MS, changed from 2.45 wt% to 2.07 wt% after 
the fifth recycling. It appears that the degree of Pd leaching caused by the 
catalyst recycling during the Suzuki polymerization was not significant.23 
 

























run Mna PDIa yield Pdreb 
1 16.2 k 2.90 >99% 52 ppm 
2 19.9 k 2.49 >99% 28 ppm 
3 17.5 k 2.82 98% 21 ppm 
4 15.3 k 2.41 >99% 5 ppm 
5 18.9 k 2.49 94% 34 ppm 
6 11.3 k 2.35 >99% 17 ppm 
average 16.5 k - >98% 26 ppm 
a Determined by THF SEC calibrated using PS standards. Mn is given in 
g/mol. b Concentration of residual Pd in polymers detected by inductively 





Table II-4. Recycle test of the Pd-Fe3O4 HNC catalyst for compare to 
sonication process 
 




















(a) recycling at 70 °C (with sonication) 
run Mna PDIa yield Pdreb 
1 17.6k 4.03 >99% 38 ppm 
2 14.2k 3.12 95% 17 ppm 
3 8.6k 2.34 95% 38 ppm 
4 12.6k 4.93 77% 28 ppm 
5 11.3k 2.42 >99% 31 ppm 
6 6.2k 3.82 34% n.d. 
7 7.0k 4.53 52% n.d. 
8 21.5k 3.05 81% n.d. 
9 14.1k 3.43 65% n.d. 
10 21.8k 7.99 82% n.d. 
11 15.1k 2.14 >99% n.d. 
 
(b) recycling at 110 °C (with sonication) 
run Mna PDIa yield Pdreb 
1 8.2k 2.37 80% 56 ppm 
2 15.9k 2.83 94% 3 ppm 
3 11.9k 2.94 87% 24 ppm 
4 8.1k 2.19 90% 4 ppm 
5 4.3k 1.58 47% n.d. 
6 13.0k 3.12 86% 21 ppm 
7 9.2k 2.78 80% n.d. 
8 5.8k 2.00 56% n.d. 
9 9.1k 2.24 68% n.d. 





(c) recycling at 70 °C (without sonication) 
run Mna PDIa yield Pdreb 
1 15.6k 3.63 95% 53 
2 n.d. 26% n.d. 
3 n.d. 17% n.d. 
a Determined by THF SEC calibrated using PS standards. Mn is given in 
g/mol. b Concentration of residual Pd in polymers detected by 
inductively coupled plasma-mass spectrometry (ICP-MS) 
 
 
Figure II-2. TEM images of Pd-Fe3O4 HNC after recycling reactions in Table 
II-4 (a). (a) before reaction (b) after 5 runs of recycling reactions (inset : after 
11 runs of recycling reactions). 
 
Next, we investigated the amount of Pd remaining in the CPs after the 
polymerization. The ICP-MS analysis of the polymers prepared from 1,4-
diiodobenzene and 9,9-didodecylfluorene-2,7-diboronic acid showed that the 
residual Pd content after the first six reactions was 26 ppm on average with the 
lowest value of 5 ppm (Table II-3). In the case of the polymer from 9,9-di(2′-
ethylhexyl)fluorene-2,7-diboronic acid, 30 and 22 ppm Pd were detected from 
the reaction at 70 and 110 °C, respectively (Table II-4 (a) and (b), respectively, 
the average value over five recycles). To make a comparison, we conducted the 
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analogous polymerization using homogenous Pd(PPh3)4 and Pd2(dba)3 and 
obtained high level of Pd residue of 1996 and 151 ppm respectively (Table II-
5). Although Pd residues could be reduced by additional rigorous purification, 
this showed that under the same conditions, the polymers prepared by the HNC 
contained much lower Pd residue. The Pd residue found in the polymer obtained 
from the Pd-Fe3O4 HNC-catalyzed polymerization is comparable to the value 
reported for the polymerization employing Pd/C catalyst (34–56 ppm for the 
Suzuki polymerization).19 Further reduction in the Pd content to a level of 32 
ppm from 53 ppm and an increase in the Mn could be achieved through the 
purification by Soxhlet extraction using methanol and acetone (Table II-5, entry 
2). 
 
Table II-5. Homogeneour Pd-catalyzed Suzuki polymerization 
 



















Entry Temp (°C) Mna PDIa Yield 
ICP-MS 
(ppm) 
1 70 4.3k 1.88  73% 1996 













































a Determined by THF SEC calibrated using PS standards. Mn is given 






In conclusion, we demonstrated successful Suzuki polymerization using 
magnetically separable Pd-Fe3O4 heterobimetallic nanocrystals as the novel 
heterogeneous catalyst. The polymerizations using the Pd-Fe3O4 HNC catalyst 
showed good reactivity to afford various moderate to high molecular weight 
polymers. After the polymerization, the catalyst was easily separated and 
recovered using an external magnet. The nanocatalyst was reused in the 
polymerization for up to the 11th run, and the catalytic activity was maintained 
throughout the recycling process. Furthermore, less Pd remained in the CPs 
compared to that obtained from the analogous homogeneous reaction. The Pd 
leaching from each run was minimal, and the recovered catalyst maintained the 
original heterodimeric shape. The CPs, thus prepared are expected to exhibit 
better electrical performance than those obtained from the reactions using 
homogeneous catalysts. Therefore, the heterogeneous Pd-Fe3O4 HNCs have a 






NMR spectra were recorded by Varian/Oxford As-500 (500 MHz for 1H, 125 
MHz for 13C). THF Gel permeation chromatography (GPC) for polymer 
molecular weight analysis was carried out with Waters system (1515 pump, 
2414 refractive index detector and 2489 UV detector) and Shodex GPC LF-804 
column eluted with THF (GPC grade, Honeywell Burdick & Jackson). Flow 
rate was 1.0 mL/min and temperature of column was maintained at 35 °C. 
Samples were diluted in 0.001-0.005 wt% by THF and filtered with a 0.20 μm 
PTFE filter before injection into the GPC. Sonication was carried out with 
Powersonic 410 model devices from Hwashin Tech. Inductively coupled 





Without additional notes, all reagents were commercially available and used 
without further purification. THF was distilled over sodium and benzophenone, 
and degassed by argon bubbling for 10 minutes before using on polymerization. 
Toluene, 1,4-dioxane, methanol, DMF were purified by solvent purification 
system using alumina column, and degassed by argon bubbling. N,N’-
dimethylacetamide (DMA) was purchased from Junsei and degassed by argon 
for 10 minutes before using on polymerization without further purification. 
 
Preparation of Pd-Fe3O4 HNCs 
 
The Pd-Fe3O4 HNCs were prepared according to the previously reported 
procedure. The synthesis was performed by one-pot thermal degradation of a 
mixture solution composed of iron acetylacetonate (14.0g, 40.0 mmol), 
palladium acetylacetonate (200 mg, 0.066 mmol), oleylamine (120 mL, 350 
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mmol), and oleic acid (80 mL, 250 mmol). The mixture was heated to 120 °C 
under reduced pressure while being vigorously stirred for 2 h. The resulting 
mixture was heated to 220 °C under Argon at a heating rate of 2 °C/min and 
kept at same temperature for 30 min. Then it was further heated to 300 °C at 
the 2 °C/min heating rate and aged for 30 min. Next the mixture was cooled to 
room temperature and washed with ethanol and a black supernatant was sore. 
The residue was dispersed in EtOH through sonication and products were 
collected by centrifugation (1750 rpm, 15 min). The Pd–Fe3O4 product was 
again dispersed in hexane and collected through the use of centrifugation (1750 
rpm, 15 min). This washing process was rerun until the sore hexane did not 
show any color. Then, the Pd-Fe3O4 HNCs was collected and dried under 
vacuum to provided 2.45 g of dark solid. 
 
 
General preparation of polymers  
 
The mixture of 1 equiv of diiodo compounds (0.3 mmol), 1 equiv of diboronic 
acid (or diboronic ester) compounds (0.3 mmol), 5 equiv of base (1.5 mmol), 2 
mol% of Pd-Fe3O4 (2 mol% loading of Pd-atom equivalents, 26 mg of 2.45 wt% 
Pd–Fe3O4) in Schlenk tube was evacuated and backfilled with argon four times, 
then degassed solvent (2-3 mL, 0.10-0.15 M) was added to the reaction mixture. 
The Schlenk tube was tightly sealed, and it was sonicated for 30 min at room 
temperature. The reaction mixture was immersed in 70 °C (or 110 °C) oil bath 
and stirred for 72 hr with stirring. The reaction mixture was cooled down to 
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room temperature, and the Pd-Fe3O4 catalyst was separated using a magnet. The 
resulting reaction mixture was diluted with chloroform, and washed with brine. 
The combined organic layers were dried with magnesium sulfate, and 
concentrated. The concentrated solution was precipitated into methanol, filtered, 
and dried under vacuum. The recovered Pd-Fe3O4 catalyst was washed many 
times by using chloroform, hexane, water, acetone, and tetrahydrofuran then it 
was dried and reused for the next run of the reaction.
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I. NS5A를 타깃으로 하는 C형 간염 치료제 연구 
 
2010 년, BMS (Bristol-Myers Squibb)사에서 개발한 디페닐계 
HCV NS5A 저해제인 다클라타스비르는 여러가지 유전자형에 매우 
높은 저해 활성으로 보여 혁신신약이라는 찬사를 받았다. 이에 
다클라타스비르의 이미다졸 작용기를 아마이드 작용기로 치환하여, 
벤지딘으로부터 3 단계 반응을 통하여 벤젠 프롤린아마이드구조의 
신규 저해제를 개발하였다. 마지막부분의 캡핑기에 구조-활성 
관계를 조사해본 결과, 비천연 아미노산의 페닐글라이신 형태가 
가장 높은 효능을 보였다. 이를 바탕으로 마지막부분의 캡핑기를 
고정한 뒤, 프롤린과 벤지딘의 유도체를 조합하여 구조-활성 관계를 
다시 확인하였다. 프롤린부분은 처음에 도입하였던 천연 아미노산의 
프롤린이 가장 좋은 활성을 보였고, 벤지딘은 오르토위치보다는 
메타위치에 치환기가 있을 경우, 항-HCV 활성이 매우 뛰어난 것을 
발견하였다. 이에 메타위치가 묶여 있는 플루오렌구조를 착안하여 
신규성이 있으면서 활성이 우수한 물질을 발견하였고, 이를 토대로 
타 기관과의 협업을 통한 전임상 후보물질 도출을 위한 물성조사, 
약동역학 테스트 및 초기 독성 조사하였다. 그 결과, 독성이 없고 




II. 팔라듐 산화철 나노입자를 이용한 컨쥬게이션된 
폴리머 합성법 
 
전기나 광전자의 성격에 영향을 미치는 컨쥬게이션된 폴리머를 
합성하는 방법에는 류테늄을 이용한 상호 교환 반응, 구리를 이용한 
클릭 화학, 팔라듐을 이용한 탄소-탄소 연결 반응 등이 있다. 
이러한 반응을 이용하기 위하여 사용하는 리간드나 전이금속은 
고분자의 파이-파이 상호작용을 통하여 항상 잔류하는 문제가 
발생하여 고분자 고유의 성질을 파악하기가 힘들었다. 해결방안으로 
반응성은 균질성의 촉매와 유사하되, 분리할 때는 비균질성 촉매의 
특성을 가지는 팔라듐 산화철 나노입자를 이용하여 스즈키 
중합반응을 수행하였다. 개발된 중합방법은 70 도의 비교적 낮은 
온도에서도 충분히 반응성이 좋음을 밝혔고, 합성된 고분자를 
하소하여 팔라듐 함량을 알아냈으며, 그 수치는 균질성 팔라듐 
촉매에 비해 월등히 최소화할 수 있었다. 또한 반응이 끝난 뒤, 
촉매를 자성을 이용하여 쉽게 회수할 수 있었고, 회수된 촉매는 
출발물질과 염기, 용매만을 추가하여 최대 11 번까지 팔라듐이 
최소화된 고분자를 얻을 수 있었다. 게다가, 11 번까지 사용한 
촉매는 처음상태의 촉매처럼 일정한 나노 크기와 모양을 유지할 수 
있었고 촉매의 팔라듐 함량도 크게 줄지 않았다. 개발된 고분자 
중합방법론은 친환경적이어서 산업에도 충분히 이용가능 할 것으로 
사료된다. 
